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FGR: fetal growth restriction 
IUGR: intrauterine growth restriction 
SGA: small for gestational age 
AGA: appropriate for gestational age 
LGA: large for gestational age 
BPD: biparietal diameter 
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EWF: estimate fetal weight 
ART: assisted reproductive technology 
CRL: fetal crown–rump length 
AMA: advanced maternal age 
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IVF in vitro fertilization 
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LBW: low birth weight 
ART: assisted reproductive technologies 
PE: preeclampsia 
IVF: in vitro fertilization 
CPM: confined placental mosaicism 
CVUE: chronic villitis of unknown etiology 
NICU: neonatal intensive care unit 
MCA: middle cerebral artery 
UtA-PI: uterine artery pulsatility index 
DA: diffuse adenomyosis 
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OE: ovarian endometrioma 









Fetal growth restriction (FGR), also known as intrauterine growth restriction (IUGR), is a common 
complication of pregnancy that has been associated with a variety of adverse perinatal outcomes. 
There is a lack of consensus regarding terminology, etiology, and diagnostic criteria for FGR and 
neonatal outcomes, with uncertainty surrounding the optimal management and timing of delivery 
for the growth-restricted fetuses. An additional challenge is the difficulty in differentiating between 
the fetus that is constitutionally small and fulfilling its growth potential and the small fetus that is 
not fulfilling its growth potential because of an underlying pathologic condition.  
 
Objectives 
The aim of this thesis was to undergo to a full review of the literature regarding terminology, 
etiology, diagnostic criteria and perinatal and postnatal outcomes for FGR.  
In particular, the main focus of the project was to ascertain the motor and neurodevelopmental 
outcome of infants with FGR. During the study period we also focused our research-line on the 
etiology of FGR, in particular by evaluating the impact of some maternal conditions, such as 





CHAPTER 1. ULTRASOUND ASSESSMENT OF FETAL BIOMETRY 
AND GROWTH 
 
Ultrasonography is widely used for the prenatal evaluation of growth and anatomy as well as for 
the management of multiple gestations. The procedure provides diagnostic findings that often 
facilitate the management of problems arising in later pregnancy.  
Abnormal fetal growth is a leading cause of perinatal morbidity and mortality in both industrialized 
and developing countries. In 2005, the World Health Organization (WHO) concluded that impaired 
fetal growth could be related to several causes: genetic factors, maternal characteristics such as 
nutrition, lifestyle including smoking, age and disease; complications of pregnancy; and the physical, 
social and economic environment (1,2). These disorders includes fetal growth restriction (FGR), also 
referred to as intrauterine growth restriction (IUGR) and often associated with small-for-gestational 
age (SGA), and large-for-gestational age (LGA), which may lead to fetal macrosomia.  
Screening for fetal growth abnormalities is an essential component of antenatal care, and fetal 
obstetric ultrasound plays a key role in assessment of these conditions (3).  
The fetal biometric parameters most commonly used are biparietal diameter (BPD), head 
circumference (HC), abdominal circumference (AC) and femur diaphysis length (FL). These biometric 
measurements can be used to estimate fetal weight (EFW) using various different formulae (3). It is 
important to differentiate between the concept of fetal size at a given timepoint and fetal growth, 
the latter being a dynamic process, the assessment of which requires at least two ultrasound scans 
separated in time. Maternal history and symptoms, amniotic fluid assessment and Doppler 
velocimetry can provide additional information that may be used to identify fetuses at risk of 
adverse pregnancy outcome. Accurate estimation of gestational age is fundamental for determining 
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whether fetal size is appropriate-for-gestational age (AGA). Except for pregnancies obtained from 
assisted reproductive technology (ART), the date of conception cannot be determined precisely. 
Clinically, most pregnancies are dated by the last menstrual period, though this may sometimes be 
uncertain or unreliable. Therefore, dating pregnancies by early ultrasound examination at 8–14 
weeks, based on measurement of the fetal crown–rump length (CRL), appears to be the most 
reliable method to establish gestational age. Once the CRL exceeds 84 mm, HC should be used for 
pregnancy dating (4-6). HC, with or without FL, can be used for estimation of gestational age from 
the mid-trimester if a first-trimester scan is not available and the menstrual history is unreliable. 
When the expected delivery date has been established by an accurate early scan, subsequent scans 
should not be used to recalculate the gestational age (3). Serial scans can be used to determine if 
interval growth has been normal. 
 
CHAPTER 1.1 Fetal measurements: what should be measured, when and how? 
 
CRL should be used to assess fetal size and to estimate gestational age up to 14 weeks of gestation.  
After 14 weeks, usual measurements include BPD, HC, AC and FL (3,4). All measurements can be 
acquired transabdominally or transvaginally. Clear images with appropriate magnification and 
correct depiction of landmarks are needed to allow precise caliper placement (3). Calipers should 
be placed as described in the charts that are chosen for gestational age or size determination.  
A review of measurement techniques and pitfalls can be found online on the INTERGROWTH-21st 
Website (7). The HC and AC measurements, can be acquired with two possible methods, which are 
equally reproducible: using the ellipse tool and the two-diameters method; in both cases the 
calipers should be placed in an outer-to-outer position (15). It is essential that, within an institution 
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or a referring hospital’s local or national network, the same method is used, and that this is the 
same as that adopted in the studies which produced the reference curves being used. 
 
CHAPTER 1.2 Estimated fetal weight 
 
EFW could be used to monitor fetal size and growth (4). EFW helps clinicians to assess fetal growth, 
depending on which size parameters are included; use of the same anatomic parameter(s) for 
monitoring growth prenatally and postnatally; and communication and management with parents 
and pediatricians regarding the anticipated birth weight.  
However, use of EFW also carries some disadvantages (10,11): in particular, errors in single-
parameter measurements are frequent; accuracy of EFW is compromised by large intra- and 
interobserver variability, with errors in the range of 10–15% (12). Given the errors inherent in EFW, 
the time interval between two scans should be at least 2-3 weeks, to minimize false-positive rates 
for the detection of fetal growth disorders, although this recommendation does not preclude more 
frequently performed scans when clinically indicated (19). However, monitoring of fetal status may 
require interval scans with no EFW evaluation.  
Quality control in fetal biometry is crucial for auditing and monitoring purposes. Image storage and 
review, and assessment of intra- and interobserver reproducibility are fundamental for a good 
quality-control strategy (5,14,15). Quality control of images for CRL, HC, AC and FL measurement 







Table 1. Criteria for score-based objective evaluation of quality of biometric images 
Type of image 
Cephalic                                                     Abdominal                                               Femoral 
Symmetrical plane Symmetrical plane Both ends of bone clearly visible 
Plane showing thalami Plane showing stomach bubble < 45° angle to horizontal 
Plane showing cavum septi 
pellucidi 
Plane showing portal sinus Femur occupying more than half 
of total image 
Cerebellum not visible Kidneys not visible Calipers placed correctly 
Head occupying more than half 
of total image 
Abdomen occupying more than 
half of total image 
 
Calipers and dotted ellipse 
placed correctly 







CHAPTER 1.3 Which metric should be used in describing fetal biometric and which 
cut-off to define abnormal biometry? 
 
Measurements acquired on fetal ultrasound can be recorded as raw data, expressed in mm or cm. 
Because measurements and their distributions change with advancing gestational age, centiles, Z-
scores, percentage deviation from the mean or multiples of the median (14) may also be used when 
referring to raw data of a reference range. Assuming the underlying 
normality of distribution of the measured parameter, centiles or Z-scores are measures of deviation 
from the mean of a population. The use of Z-scores has several advantages, including that the scale 
is linear, allowing comparison between different biometric variables at different gestational ages 
(18). Centiles are intuitively more understandable than are Z-scores and there is a precise 
 10 
relationship between them when there is a standard normal distribution of the population (5th 
centile is equivalent to –1.64 Z-score; 10th centile is equivalent to –1.28 Z-score), (19). 
AC and/or EFW below the 10th centile for gestation is a commonly accepted definition of FGR. 
However, this cut-off value changes depending on the chart used. Moreover, most SGA babies are 
not growth-restricted at birth, and some babies with FGR due to placental insufficiency who are at 
risk of compromise or stillbirth are AGA (20). An international Delphi consensus recently proposed 
that a cut-off of AC or EFW below the 3rd centile may be used as the only diagnostic parameter for 
FGR (21). In case of AC or EFW below the 10th centile, the diagnosis of FGR should be made only in 
association with other parameters (Table 2). Depending on the gestational age, these include 
maternal (uterine artery) or fetal (umbilical or cerebral/umbilical artery) Doppler findings or a drop 




CHAPTER 1.4 Screening for FGR and/or SGA foetuses 
 
A routine mid-trimester ultrasound scan is typically performed between 18 and 22 weeks of 
gestation (22). This period represents a compromise between dating the pregnancy (more accurate 
if established earlier) and the detection of major congenital anomalies. The performance of or need 
for any additional third-trimester scans is based on local guidelines, and the presence or absence of 
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maternal or fetal conditions and of risk factors that are known to be associated with abnormal 
growth (23). 
Additional scans could be beneficial for monitoring fetal wellbeing  and for subsequent detection of 
fetal growth abnormalities (24). Ultrasound examination at 36weeks’ gestation was found to be 
more effective than that at 32 weeks’ gestation in detecting FGR and predicting related adverse 
perinatal and neonatal outcome (25). Future research should include more accurate sonographic 
detection of FGR infants, to identify a small fetus at risk for morbidity and to determine 
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CHAPTER 2. ULTRASOUND CHARTS OF FETAL SIZE 
 
Recent publications (1-5), editorials and correspondence, (6-9) as well as presentations and debates 
at national and international meetings, have activated a controversy that goes well beyond the 
boundaries of obstetrics and perinatal medicine. The controversies touch upon fundamental topics 
in biology, genetics, politics, and human rights.  
At present, clinicians around the world are using many different ultrasound charts of fetal size, 
based on a variety of populations and methodologies, to monitor growth. All these charts are 
references rather than prescriptive standards. The distinction is critical.  
References describe how individuals have grown at a particular time and place, often decades 
beforehand. Prescriptive standards, on the other hand, are purposely developed using a selected, 
healthy population, to describe how humans should grow when nutritional, environmental, and 
health constraints on growth are minimal. They are based conceptually on the WHO 1995 
recommendation that “human growth should be evaluated using international standards, 
describing how individuals should grow”, (10). 
 
 
Chapter 2.1 The INTERGROWTH-21st fetal growth standards 
 
The INTERGROWTH-21st project was a comprehensive evaluation of human growth and 
development across the first 1000 days of life, leading to the construction of fetal and preterm 
postnatal growth standards; it included an assessment of newborn body composition, infant feeding 
practices, and preterm postnatal growth, as well as postnatal growth and neurodevelopment 
evaluation at 2 years of age to assess the appropriateness of the complete cohort for the 








The first step in creating prescriptive international standards of optimal fetal growth was to select 
free-living populations in defined geographic areas with minimal constraints on growth, and good 
maternal and perinatal health outcomes. The second step was to select, from the whole population, 
healthy pregnant women at low risk of adverse outcomes, (11) Healthy pregnant women with a 
naturally conceived singleton pregnancy, who met the individual inclusion criteria (11) were 
identified prospectively in the INTERGROWTH-21st project.  
Women were recruited <14 weeks’ gestation, and pregnancies were dated based on a certain last 
menstrual period, but corroborated by ultrasound measurement of the CRL, (12) Ultrasound scans 
were then performed every 5  1 weeks from the initial dating scan by dedicated research staff 
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using identical, midrange ultrasound machines at each study site, with rigorous training and 
standardization procedures (13,14) quality control measures (15), and blinding of measurements. 
Moreover, unlike any other longitudinal study of ultrasound in pregnancy, the infants involved in 
the fetal growth standards were followed up for 2 years after birth, using the same standardized 
methods employed in the WHO child growth standards to measure growth (16) neurodevelopment, 
auditory processing, and sleep-wake patterns at 2 years of age (3)  
The INTERGROWTH-21st Project aimed to produce, for the first time (panel), international standards 
for newborn size for each gestational age based on data from its Newborn Cross-Sectional Study 
subpopulation, which conformed at population and individual levels to the prescriptive approach 
used in the WHO Multicentre Growth Reference Study (MGRS) (16) 
These new standards are considered to be a conceptual and practical link to WHO Child Growth 
Standards, which have been adopted by more than 125 countries worldwide (17,18). The purpose 
is to bridge gaps in clinical and population assessments for fetuses, neonatal babies, and infants 
through provision of similar instruments to monitor child growth seamlessly from early pregnancy 
to age 5 years and to screen for stunting and wasting.  
The INTERGROWTH-21st Project therefore is an international, sex-specific standards for weight, 
length, and head circumference for gestational age at birth that complement the available WHO 
Child Growth Standards and allow comparisons across populations. The international standard for 
length at birth for gestational age, in particular, when incorporated into routine neonatal care, will 
provide a method for the early diagnosis of stunting, which can be then be monitored during infancy 







2.2 Customized growth charts 
 
Customized charts adjust for constitutional or physiologic variation and exclude pathologic factors 
that affect growth, thereby defining an optimized standard that represents the growth potential of 
each individual fetus (19,20). As a result, they improve the prediction of birthweight in an 
uncomplicated pregnancy and improve the identification of abnormal growth.  
In the customized model, the variables for adjustment are derived from birthweights of normally 
formed fetuses who were delivered at the end of uncomplicated pregnancies at term. The 
physiologic variables that significantly affect birthweight are consistent in many cohort studies and 
are quantified through multivariable analysis: fetal sex, maternal height, weight in early pregnancy, 
parity, and ethnic origin. Adjustment for maternal height and weight is made within normal body 
mass index (BMI) limits only (19). Pathologic factors that are known at the beginning of pregnancy 
include hypertension, diabetes mellitus, smoking, and low and high BMI. Social deprivation may 
appear in the univariate analysis but does not tend to remain significant after adjustment for other 
factors, such as smoking and abnormal BMI (21). The model adjusts for the physiologic but not 
pathologic variables, and results in a constant that represents an expected optimal birthweight at 
the end of an uncomplicated pregnancy. 
The use of customized percentiles is recommended by the Royal College of Obstetricians and 
Gynaecologists Guidelines (22) for the assessment of birthweight and antenatal surveillance of fetal 
growth. Customized percentile calculators are freely available via the Gestation Network 
(www.gestation.net) that is administered by the Perinatal Institute and have been or are currently 
in use by over 300 clinicians and researchers in 30 countries. They can be applied in case-by-case 
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CHAPTER 3. FETAL GROWTH RESTRICTION (FGR)  
 
CHAPTER 3.1 Terminology 
 
FGR is defined as a rate of fetal growth that is less than normal for the growth potential of a specific 
infant as per the race and gender of the fetus. The terms FGR and SGA are often used 
interchangeably, although there are substantial differences between the two (1).  
The term SGA define those fetuses whose weight is less than (less than 10th percentile for that 
particular gestational age) the population norms on the growth charts, however SGA refers only to 
birth weight without consideration to in-utero growth and placental function during pregnancy. On 
the contrary, FGR occurs when the fetus does not reach its intrauterine potential for growth and 
development as a result of compromise in placental function. A FGR infant may have an appropriate 
birth weight as per gestation, but may have suffered from intrauterine growth restriction as a 
consequence of a perinatal insult, thus FGR is a clinical definition and applied to infants with clinical 
evidence of malnutrition. It is important to keep in mind that neonate with a birth weight less than 
the 10° percentile may be SGA, but not FGR, and a neonate with a birth weight greater than the 10° 
percentile may be FGR (2).  
 
CHAPTER 3.2 Epidemiology 
 
It is estimated that approximately 11% of all total neonates delivered in developing countries are 
born every year at term with low birth weight (LBW), and this incidence is six time higher when 
compared to developed countries. The incidence of FGR fetuses varies among countries, 
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populations, races and increases with decreasing gestational age. The main incidence of these FGR 
infants is in Asia, which accounts for nearly three-fourth of all affected infants, followed by Africa 
and Latin America. For LBW and FGR-LBW respectively, the highest incidences are detected. At the 
national level, the highest incidences for LBW and FGR-LBW respectively are: Bangladesh (50%, 
39%), India (28%, 21%) and Pakistan (25%, 18%), followed by Sri Lanka (19%, 13%); Cambodia (18%, 
12%); Vietnam and the Philippines (11%, 6%); Indonesia and Malaysia (8%, 4%); Thailand (8%, 3%) 
and the People’s Republic of China (PRC) (6%, 2%), (3).  
FGR is an intercurrence in 5–10% of pregnancies (4). It is the second leading cause of perinatal 
mortality and is responsible for 30% of stillborn infants; it is also the most common cause of 
premature births and intrapartum asphyxia. 
 
CHAPTER 3.3 Etiology 
 
The etiology of FGR can be broadly categorized into maternal, fetal, and placental. Although the 
primary pathophysiologic mechanisms underlying these conditions are different, they often (but not 
always) have the same final common pathway: suboptimal placental perfusion and fetal nutrition. 
 
• Chapter 3.3.1 Maternal factors 
 
Race and maternal age (less than 16 years and more than 35 years) have been found to be risk 





















Low socioeconomic status and living in a developing country is an independent risk factor for FGR. 
Low socioeconomic status is more often related to the mother’s poor nutrition as well as substance 
abuse, whereas living in a developing country is associated with maternal anemia or malnutrition, 
which leads to FGR (7).  
Advanced maternal age (AMA) is defined as childbearing in a woman over 35 years of age and is a 
growing trend with In high-income countries (8). This trend is most commonly attributed to older 
primigravid women who delay childbearing by lifestyle choice or due to underlying subfertility, but 
also includes multiparous women continuing childbearing (9). Women in both groups have 
benefited from advancements in assisted reproductive technologies (ART). AMA is reported to be 
associated with a wide range of pregnancy complications including: FGR, preeclampsia (PE), 
placental abruption, preterm birth and stillbirth (10,11) and importantly these increased risks 
appeared to be independent of maternal co-morbidities (12,13).   
• Maternal age 
• Altitude 
• Socioeconomic status 
• Ethnicity or race 
• Maternal substance abuse 
• Maternal medication 
• Maternal height and weight 
• Parity 
• Inter pregnancy interval 
• Previous delivery of SGA newborn 
• Assisted reproductive technologies 
• Failure to obtain normal medical care in pregnancy 
• Severe maternal starvation 
• Hematologic medical disorders 
• Maternal medical disorders 
• Pathological conditions in pregnancy like preeclampsia 
and diabetes associated with vasculopathy 
• Maternal infection and parasite infestations 
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Maternal diseases that have an impact on blood circulation, may frequently cause a decrease in 
uteroplacental blood flow and lead to FGR. These various diseases include hypertensive disorders 
(gestational and non-gestational), diabetes associated with vasculopathy, chronic renal disease, 
systemic lupus erythematosus, antiphospholipid syndrome, sickle cell disease and others. Acquired 
thrombophilia, such as anti-cardiolipin antibodies and lupus anticoagulant, can cause poor 
pregnancy outcomes, such as early-onset preeclampsia and fetal stillbirth in addition to FGR. On the 
contrary, inherited thrombophilia polymorphisms (namely anti-thrombin III deficiency, factor V 
Leiden, protein C and S deficiencies) did not result in FGR (14). 
The use of ART is a risk factor for FGR both independently in singleton pregnancies and also as a 
result of multiple gestation pregnancies . Singleton pregnancies obtained with ART has been shown 
to  be  related  with  adverse  obstetrical  and  perinatal  outcomes,  but  this  is  challenging  literature  
to  analyse. In  almost  all  studies  of   singleton  pregnancies  resulting  from  any  type  of   ART,  
LBW  is  found  more  often  than  in  spontaneous  pregnancies (15). Many  emerging  studies  are  
trying  to  identify  the  causative  factors  responsible  for  growth  disturbance  in  women 
undergoing ART by comparing outcomes in various subsets within cohort studies of  the AHR 
population and with  outcomes  in  spontaneous  pregnancies.  Sasanova et al. performed logistic 
regression  analysis  on  8941  singleton  pregnancies  after  in vitro fertilization (IVF) to determine 
predictive factors for preterm birth and LBW. They found that primiparity, smoking, BMI, and the 
vanishing twin phenomenon increased the risk of  preterm birth, and that maternal age, smoking, 
and duration of  infertility increased the risk of  LBW (16).   
Women in the lowest quartile of both low pre- pregnancy weight, and pregnancy weight gain are at 
the highest risk of producing an FGR infant (17). A short and longer inter-pregnancy interval has 
been found to be associated with FGR. Zhu et al. showed that when compared to infants conceived 
18–23 months after a live birth, infants conceived less than six months after a live birth had higher 
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odds for low birth weight, preterm birth and SGA; and similarly the infants conceived 120 months 
or more after a live birth had higher chances of adverse outcomes even when controlled for other 
confounding variables (18). 
Cigarette smoking is a common cause of FGR (19-21).  There  are  a  number  possible  of  
mechanisms,  including  nicotine-induced  placental  vasoconstriction  (22)  and  the  effects  of 
carbon monoxide on mitochondrial function (23). Research  on  rats  has  shown  that  nicotine  
damages  the  fetal  pancreatic  mitochondria  leading  to  beta  cell  dysfunction  and  apoptosis.  
This  causes  impaired  glucose  tolerance  in  the  off-spring, which may be irreversible if nicotine 
exposure continues during  lactation  (24).  Inadequate  insulin  production  in  the  fetus  would  
impair  glucose  uptake ,  which  could  be  a  contributory  mechanism  for  the impaired fetal  
growth.  An  adverse  effect of maternal smoking may persist into childhood; children exposed  to  
cigarette  smoke  in  utero  tend  to  have  a  higher  body  mass index (BMI), which is not totally 
attributable to their lower birthweight  (25),  and  there  are  also  gender  differences  in  the  
childhood growth patterns, with greater weight gain in boys (26). Cigarette smoking also 
predisposes to gestational diabetes (27). 
Passive smoking has also been associated with FGR. A cross-sectional study performed by Goel et 
al.  assessed the effects of passive smoking during pregnancy and found out that women who have 
been exposed to passive smoking had significantly higher incidence of preterm birth and SGA babies 
as compared to unexposed mothers (28). Similar results were shown by study from Malaysia that 
reported a significant association between second hand smoke exposure during pregnancy and LBW 
(29).  
Heavy maternal drinking is associated with fetal alcohol syndrome, whereas moderate alcohol 
consumption has been associated with FGR (30,31). Toxic exposures of mother, including various 
medications, such as warfarin, steroids, anticonvulsants, antineoplastic agents, anti-metabolite and 
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folic acid antagonists result in FGR (32). Maternal intake of illicit drugs like marijuana or cocaine 
during pregnancy is associated with impaired fetal growth (33). 
Maternal infection and parasite infestations, such as TORCH, malaria, tuberculosis, urinary tract 
infections and bacterial vaginosis has been implicated in FGR (34).  
Several studies have reported in the last decade a correlation between endometriosis and major 
adverse obstetric outcomes, such as spontaneous late miscarriage, preterm prelabor rupture of the 
membranes and preterm birth, SGA, hypertension, preeclampsia, gestational diabetes, obstetric 
hemorrhage and placenta previa (35-37). Theoretically, some pathogenic mechanisms might explain 
the higher risk of obstetric complications in women with endometriosis; these mechanisms include 
endometrial resistance to selective actions of progesterone, inflammation, inadequate uterine 
contractility, endometrial excessive activation of free radical metabolism and abnormal 
trophoblastic invasion into the ‘myometrial junctional zone’ due to partial or absent remodeling of 
the myometrial spiral arteries (38). However, other studies and a systematic review did not confirm 
completely these findings (39).  
 
• Chapter 3.3.2 Placental factors 
 
The placenta is a complex organ with a biologically short existence and it is the only organ formed 
by cells from two different organisms. The placenta is an essential organ for the transfer of nutrients 
and gases from the mother to fetus and for the elimination of products resulting from fetal 
metabolism. Blood flows to the uterus through the uterine arteries, irrigating and providing 
nutrients to the intervillous space, which is composed of 100–200 uteroplacental arteries. It also 
includes about 75–175 veins, which provide oxygenated blood to the fetus (40).  
 27 
The placenta has also the function of a barrier, protecting the fetus from different pathogens. 
Moreover, It has the ability to act as an endocrine organ, because it is able to synthetize  and realize 
hormones, growth factors, and cytokines (41).  
The interaction between maternal and fetal circulations within the placenta is fundamental for 
adequate exchange of nutrients and oxygen. It is hypothesized that this adaptation comes from a 
physiological process referred to as “waves of trophoblast migration”.  Cytotrophoblast invasion, 
during the first trimester of pregnancy, happens in the decidual tissue, including the intradecidual 
segments of the spiral arteries. The second migration occurs between the 16th and 18th weeks, 
when endovascular invasion extends to the myometrial segments of the spiral arteries that lose the 
musculoskeletal layer, which is replaced by the fibrin matrix. This process leads to a drop in vascular 
resistance, in addition to less responsiveness to local vasoconstricting agents (42, 43). 
Abnormal placentation has been defined as a condition in which trophoblast invasion of the 
myometrial portion of the spiral arteries does not occur (44). Reduced uteroplacental perfusion 
associated with maternal vascular disease is responsible for 25–30% of FGR cases; it is the most 
common cause in non-anomalous fetuses. 
Placental weight has fundamental role in FGR determination. In 2001 Heinonen et al. evaluated the 
association between placental weight and birth weight in AGA and SGA infants. What they found 
was that placenta of SGA infants was 24% smaller in size than that of AGA infants. Placental actual 
weight was also lower in SGA infants than in AGA infants of the same birth weight (45). 
Structural abnormalities and changes in placental implantation and attachment may also be 
involved in the etiology of FGR, including bilobed placenta, low-insertion placenta, chorioangioma, 
velamentous insertion of the umbilical cord, and presence of a single umbilical artery. These 
anomalies may lead to a decreased transfer of nutrient and oxygen to the fetus, leading to FGR (46, 
47).  
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Confined placental mosaicism (CPM) are chromosomal anomalies (usually involving a trisomy) 
found in the placenta, but not in the fetus. Wilkins-Haug et al. in their study evaluated 70 FGR infants 
and 70 AGA infants and reported that CPM occurred significantly more in FGR infants placentae 
compared to AGA infants with high-level tetraploidy among the FGR placentae. These placentae 
histologically had greater decidual vasculopathy, infarction and intervillous thrombus formation 
predominantly in the karyotypically abnormal placentae (48).  
Chronic villitis of unknown etiology (CVUE), is characterized by focal areas of inflammation with 
mononuclear cells and areas of fibrinoid necrosis in chorionic villi, and is a diagnosis of exclusion. 
CVUE is detected in 7– 33% of placentas, mainly with FGR, unexplained prematurity, preeclampsia, 
perinatal asphyxia and intrauterine fetal death (49). 
 
• Chapter 3.3.3 Fetal factors 
 
Fetal chromosomal abnormalities account for 7–19% of total FGR infants born (Table 2). The most 
common chromosomal anomalies are trisomies, in particular trisomy 21 (Down syndrome), trisomy 
13 (Patau syndrome) and trisomy 18 (Edwards syndrome).  
 








• Chromosomal abnormalities 
• Genetic syndromes 
• Major congenital anomalies 
• Multiple gestation 
• Congenital infections 
• Metabolic disorders 
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A study published in 1993, reported incidence of chromosomal abnormalities of 19% in FGR 
foetuses, with most common chromosomal defect in the group referred before 26 weeks of 
gestation being triploidy and thereafter most common being trisomy 18 (50). Another study, 
published by Anandakumar et al. reported incidence of chromosomal defects of 9.9% in the FGR 
fetuses (51). The pathogenesis that has been purposed is the reduction of number of small muscular 
arteries in the tertiary stem villi of the placenta and also increased vascular resistance of the 
placenta (52). 
Many congenital anomalies have been found to be associated with FGR. The most common ones 
includes tracheo-esophageal fistula, congenital heart disease (53), congenital diaphragmatic hernia 
(54), abdominal wall defects, such as omphalocele and gastroschisis, neural tube defect like 
anencephaly and anorectal malformation. Congenital malformations, account for approximately 1–
2% of FGR. Khoury et al. performed a population-based study and found out that the incidence of 
FGR among malformed infants was 22,3% (relative risk 2,6) and also reported that the frequency of 
FGR increased with increasing number of defects in the infant from 20 to 60% (55).  
Congenital infection are responsible for about 5% of the total FGR cases. In developed countries, 
the most common infections are toxoplasmosis and cytomegalovirus, while it has been observed a 
reduction of rubella because of vaccination and the strategy for routine screening for TORCH (56). 
In the developing countries the common causes are malaria, congenital HIV infection, syphilis and 
rubella. In Africa and South-East Asia, malaria is the predominant infectious disease and account for 
40% of cases in places where it is endemic (57, 58). Malaria activates immune-mediated 
inflammatory processes and platelets, which deposit in the vascular system and lead to vessel 
obstruction and decrease nutrition supply to fetus leading to FGR (59).  
Multiple gestations are reported to be associated with about 3% of cases of FGR. This is more 
common in monochorionic twins or higher order gestation. The growth velocity in twin pregnancies 
 30 
is usually normal till 28 weeks of gestation and then there is a physiological decrease in the growth 
rate. A growth discordant of 15% or greater occurs in around 30% of twin pregnancies, and it has 
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CHAPTER 4 STUDY 1:  
Influence of adenomyosis on pregnancy and perinatal outcomes 
in women with endometriosis 
 
INTRODUCTION 
Endometriosis and adenomyosis are defined by the presence of endometrial glands and stroma, 
located outside the uterus and in the myometrial wall, respectively (1). The eutopic endometrium 
and the inner myometrium in patients affected by endometriosis and/or adenomyosis show several 
functional and structural abnormalities (1). These differences seem to be related mainly to 
abnormal expression of genes involved in local estrogen production and response to progesterone, 
an altered oxidative stress response, and the presence of cytokines, inflammatory mediators and 
apoptotic markers (2,3). In the past 10 years, several studies have reported a correlation between 
endometriosis and major adverse obstetric outcomes, such as spontaneous late miscarriage (4), 
preterm prelabor rupture of the membranes and preterm birth (5–11), small-for-gestational age 
(SGA), (5,10), hypertension (9), pre-eclampsia (5,8,11), gestational diabetes (10), obstetric 
hemorrhage (such as abruptio placentae and postpartum bleeding) (5,9,11) and placenta previa (5–
7,9,12). 
However, other studies (12,13) and a systematic review (14) did not confirm completely the 
increased risk of obstetric complications in women with endometriosis. Theoretically, some 
pathogenic mechanisms might explain the higher risk of obstetric complications in women with 
endometriosis; these mechanisms include endometrial resistance to selective actions of 
progesterone, inflammation, inadequate uterine contractility, endometrial excessive activation of 
free radical metabolism and abnormal trophoblastic invasion into the ‘myometrial junctional zone’ 
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due to partial or absent remodeling of the myometrial spiral arteries (15). It is well known that there 
is a strong association between endometriosis and adenomyosis16. The reported prevalence of 
adenomyosis in patients affected by endometriosis ranges widely between 20% and 50% (17–19) 
and its association seems to be related to increasing age, parity, dysmenorrhea intensity and 
presence of deep infiltrating endometriosis (DIE), (20). Previous studies also showed that women 
with adenomyosis are at increased risk of some adverse pregnancy outcomes, such as preterm 
delivery, preterm prelabor rupture of membrane, SGA and fetal malpresentation (21–23). However, 
despite this background, previous studies have given little attention to the influence of adenomyosis 
on the pregnancy outcome of patients with endometriosis. On the basis of these premises, the aim 
of the present study was to evaluate maternal and fetal outcomes in a cohort of women with 
endometriosis with or without the concomitant presence of diffuse or focal adenomyosis. 
 
METHODS 
Study design and study population 
This study was based on a retrospective analysis of data collected prospectively between January 
2014 and December 2016. The study protocol was approved by the regional ethics committee. 
Patients included in the study signed a general consent form for the use of their data for scientific 
purposes. This study included pregnant women who had ultrasonographic and/or histological 
diagnosis of endometriosis with or without ultrasonographic diagnosis of focal or diffuse 
adenomyosis prior to conception. The ultrasonographic exams were performed at any phase of the 
menstrual cycle, regardless of the use of hormonal therapy. Standardized ultrasound criteria were 
used for the diagnoses of DIE (24) and endometriomas (25). The ultrasonographic diagnosis of 
adenomyosis was made if two or more of the following features were present: asymmetrical 
myometrial thickening, myometrial cysts, linear striations, hyperechoic islands or an irregular and 
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thickened endometrial–myometrial junctional zone on either two- or three-dimensional imaging 
(26,27). On ultrasonography, focal adenomyosis was defined as the presence of adenomyosis-
related lesions in only one part of the myometrium, while diffuse adenomyosis was defined as the 
presence of ill-defined lesions in more than one site within the uterine wall, more often being 
dispersed within the myometrium rather than forming a confined lesion (28). 
The patients included in the study were divided into three groups: those with endometriosis and 
focal adenomyosis, those with endometriosis and diffuse adenomyosis and those with 
endometriosis only. Women with previous uterine surgery or uterine malformation, pregnancies 
with major fetal structural abnormality, chronic hypertension, known autoimmune disease or fetal 
aneuploidy, and multiple gestations were excluded. 
Pregnancies were dated by measurement of crown–rump length in the first trimester according to 
the National Institute for Health and Care Excellence (NICE) guidelines (29). Pregnancy-associated 
plasma protein-A (PAPP-A) levels were measured at the time of routine 11–14-week first-trimester 
combined screening test for Down syndrome. Uterine artery (UtA) Doppler indices were measured 
in all women at the 11–14-week examination and at the time of the routine anomaly scan between 
19 and 23weeks of gestation. UtA Doppler assessment was performed transabdominally (30). The 
pulsatility index (PI) of the left and right UtAs was averaged to compute a mean PI and plotted 
against a published reference range (30). All patients underwent a growth scan during the third 
trimester of pregnancy between 29 and 34weeks of gestation to evaluate growth of the fetus. Low-
dose aspirin for prevention of pre-eclampsia was not used during the study period. Ultrasound 
assessments were performed using a GE Voluson E6 ultrasound machine (GE Medical Systems, Zipf, 
Austria). Maternal characteristics, including age, body mass index (BMI), ethnic origin and mode of 
conception (spontaneous or in-vitro fertilization), were recorded during the first visit and pregnancy 
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outcomes were collected. Delivery or follow-up scans were arranged as appropriate for any 
suboptimal assessments. 
Gestational complications were defined as follows: preterm birth as delivery before 37 completed 
weeks of gestation; pregnancy-induced hypertension as blood pressure persistently over 
140/90mmHg that developed after 20weeks of gestation in a previously normotensive woman; pre-
eclampsia as gestational hypertension and proteinuria (>300 mg/24 h); and SGA as birth 
weight<10th centile for gestational age. 
 
Statistical analysis 
Data distribution was assessed according to the Kolmogorov–Smirnov test of normality. Data were 
expressed as mean±SD, or median and interquartile range. Categorical variables were described as 
number (%). The correlation between continuous variables was assessed using Pearson’s coefficient 
or Spearman’s rho. Pearson’s chi-square test was used to analyze categorical variables. Student’s 
independent t-test and the Mann–Whitney U-test were used to compare continuous variables, as 
appropriate. Mean UtA-PI Z-score and birth-weight centile were calculated from the appropriate 
reference ranges (30). Mean UtA-PI was corrected for gestational age and multiples of the median 
were calculated based on reference ranges from the published centiles (30). Logistic regression 
analysis was used to assess the associations of maternal characteristics, first- and second-trimester 
markers, and fetal outcome with SGA in women with endometriosis and diffuse adenomyosis and 
those with endometriosis and focal adenomyosis. P<0.05 was considered statistically significant. 
Statistical analysis was performed using the statistical software package SPSS Statistics version 20.0 





Demographic and pregnancy characteristics of the three groups of patients are presented in Tables 
1 and 2. During the study period, 206 pregnant women with endometriosis were recruited into the 
study and completed the required follow-up. Among these patients, 148 (71.8%) had endometriosis 
only, 38 (18.4%) had focal adenomyosis and 20 (9.7%) had diffuse adenomyosis. Compared with 
women with endometriosis only, those presenting with diffuse adenomyosis had significantly lower 
BMI and first-trimester PAPP-A level, and significantly higher first-trimester and mid-pregnancy 
mean UtA-PIs. The prevalence of a SGA fetus, calculated according to ultrasound-estimated fetal 
weight centile at the third-trimester ultrasound assessment, was significantly different between 
women with endometriosis only (10.8%) and those with diffuse adenomyosis (30%, P<0.05). These 
results were confirmed after delivery, with the prevalence of SGA birth in women presenting with 
endometriosis only and that in women with diffuse adenomyosis being 10.8% (n=16) and 40% (n=8), 
respectively (P<0.05). No statistically significant difference was found in 5-min Apgar score or in the 
prevalence of pre-eclampsia between the two groups of patients (Table 1). 
Compared with women with endometriosis only, those presenting with focal adenomyosis did not 
have significantly different maternal demographics, first-trimester PAPP-A level, first-trimester and 
mid-pregnancy mean UtA-PIs, estimated fetal weight centile or prevalence of SGA fetus. Moreover, 
no statistically significant difference was found in prevalence of SGA at birth, 5-min Apgar score or 
prevalence of pre-eclampsia between the two groups (Table 1). Logistic regression analysis was used 
to assess the relationships of maternal and pregnancy characteristics with SGA at birth in those with 
diffuse adenomyosis and those with focal adenomyosis (Table 2). The presence of diffuse 





Table 1. Demographic and ultrasound variables and outcome in pregnant women with 
endometriosis, subdivided into those with associated diffuse adenomyosis (DA), those with 
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miscarriage (n, %) 
4 (10.5) 0.252 
1 (5.0) 0.940 8 (5.4) 





/ / / / 47 (31.8) 
USG diagnosis of 
endometriosis (n,%) 












8 (21.0) 0.672 5 (25) 0.947 36 (24.3) 
Uterosacral 
endometriotic 
nodule, (n, %) 




Data are shown as median (interquartile range), mean (standard deviation) or number (%). 
 
Assisted Reproductive Technologies: ART; Endometriosis and Focal Adenomyosis: EFA; Body Mass 
Index: BMI; pregnancy-associated plasma protein A: PAPP-A; beta human chorionic gonadotropin: 







0 (0) 0.471 0 (0) 0.601 2 (1.3) 
1st and 2nd trimester variables 
PAPP-A (MoM, 
median, IQR) 

















Mean UtA PI 1st 
trimester (median, 
IQR) 
1.61 (0.45) 0.526 2.23 (0.63) <0.05 1.67 (0.53) 
Mean UtA PI 2nd 
trimester (median, 
IQR) 
0.92 (0.22) 0.669 1.30 (0.47) <0.05 0.94 (0.28) 
Scan assessment during the 3rd trimester of pregnancy 










EFW (g, mean, SD) 1850 (268) 0.671 1661 (265) <0.05 1873 (301) 
EFW centile (mean, 
SD) 
49.6 (34.6) 0.755 29.0 (20.9) <0.05 51.5 (32.0) 
SGA fetuses (n,%) 8 (21.1) 0.093 6 (30) <0.05 16 (10.8) 










Birth Weight (mean, 
SD) 
3250 (643) 0.517 2883 (397) <0.05 3315 (523) 
Birth weight 
(centile, mean, SD) 
46.7 (30.5) 0.613 22.1 (19.3) <0.05 49.4 (28.7) 
SGA (n, %) 8 (21.1) 0.093 8 (40) <0.05 16 (10.8) 
5 minute Apgar <7 
(n, %) 
2 (5.3) 0.743 2 (10) 0.241 6 (4.1) 
Preeclampsia  (n, %) 6 (15.8) 0.153 4 (20) 0.089 12 (8.1) 
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Table 2. logistic regression analysis for prediction of small for gestational age at birth in women 
with endometriosis 
 
Variable OR 95% CI p-value 
BMI  1.004 0.919-1.097 0.932 
PAPP-A (MoM) 0.943 0.424-2.097 0.886 
Uterine Artery mean PI (2nd 
trimester) 
2.926 0.848-10.093 0.089 
Diffuse adenomyosis  3.744 1.158-12.099 0.027 
Focal adenomyosis 2.274 0.878-5.892 0.091 
 
Body Mass Index: BMI; pregnancy-associated plasma protein A: PAPP-A; small for gestational age: 






The study demonstrates that the presence of diffuse adenomyosis in pregnant women with 
endometriosis is associated with an increased risk of delivery of a SGA infant. When assessed in 
isolation, conventional risk factors for placental insufficiency, such as BMI, PAPP-A and mean UtA-
PI during the first and second trimesters of pregnancy, showed a strong correlation with the 
presence of diffuse adenomyosis in patients with endometriosis. At the time of the third-trimester 
ultrasound assessment, the prevalence of a SGA fetus was significantly higher in the cohort of 
patients with diffuse adenomyosis compared with those with endometriosis only, and these data 
were confirmed after delivery. After adjusting the results for potential confounding variables, such 
as BMI and PAPP-A, logistic regression analysis demonstrated that only the presence of diffuse 
adenomyosis was associated with SGA at birth, while that of focal adenomyosis was not associated 
with delivery of a SGA infant. 
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The study results strongly suggest that, in women with endometriosis, diffuse adenomyosis 
increases the risk of having a SGA infant and they support a potential causative relationship between 
diffuse adenomyosis and impaired placentation and subsequent development of SGA. 
 
Interpretation 
In the past 10 years, research has been focused on the influence of endometriosis on pregnancy 
outcome (4–13, 31–34). The data reported in the current literature are controversial and a 
systematic review concluded that there is no evidence that endometriosis has a major detrimental 
effect on pregnancy outcome (14). However, the review found a correlation between endometriosis 
and placenta previa, with odds ratios ranging from 1.67 to 15.114. In a recent retrospective case–
control study including women with a singleton pregnancy conceived by in-vitro fertilization, 
Benaglia et al. found that women with endometriosis do not have an increased risk of preterm birth, 
hypertensive disorders, gestational diabetes, SGA or large-for-gestational-age newborns and 
neonatal problems (12). In contrast, the authors confirmed that placenta previa was more common 
in women with endometriosis than in controls. Surprisingly, most published studies have not 
assessed the impact of adenomyosis on pregnancy outcome of patients with endometriosis. 
This is due to the fact that, in most of the studies, data were collected and analyzed retrospectively 
(7,12,13,31,33), based on computerized nationa (l4–6,8,11) or institutional (32) databases, or 
collected only at the time of delivery (10,34); therefore, preconceptional ultrasonographic 
assessment of adenomyosis was not performed. Very recently, a cohort study found no significant 
difference in the incidence of complications during the pregnancy and delivery of patients with 
rectovaginal DIE in those with and those without an ultrasound diagnosis of adenomyosis9. 
However, in this study, the small sample size may have limited the strength of the analysis; in fact, 
only 30 patients with posterior DIE and adenomyosis were compared with 22 patients with posterior 
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DIE without adenomyosis; furthermore, no subanalysis according to type of adenomyosis was 
performed (9). Our study investigated, for the first time in the literature, the influence of diffuse 
and focal adenomyosis on adverse pregnancy outcome in a cohort of patients with endometriosis, 
revealing that the concomitant presence of diffuse adenomyosis in pregnant women with 
endometriosis is an important risk factor for placental insufficiency and consequent delivery of a 
SGA infant. Adenomyosis seems to affect the process of junctional zone spiral artery remodeling 
from the onset of decidualization, and results in vascular resistance and increased risk of defective 
deep placentation (35). Yorifuji et al. measured blood flow in the myometrium and placenta using 
time-slip magnetic resonance angiography in women with adenomyosis who had severe fetal 
growth restriction, and they found that the uterine adenomyosis area showed abundant blood flow 
while the placenta had diminished blood flow, suggesting that unbalanced perfusion of the placenta 
may be among the possible causes of SGA (36). Furthermore, a case–control study in a cohort of 
2138 pregnant women found that those with adenomyosis have a higher rate of preterm delivery 
and preterm prelabor rupture ofmembranes, probably due to increased local inflammatory 
response and higher levels of prostaglandins found in these patients (22). More recently, a Japanese 
retrospective study based on the review of a computerized database compared the pregnancy 
outcome of 36 women diagnosed with adenomyosis before conception with that of 144 control 
women without uterine abnormality (23). 
The authors found that women with adenomyosis have higher risks of preterm delivery, preterm 
prelabor rupture of membranes, SGA infant, fetal malpresentation and Cesarean delivery (23). In 
agreement with these findings, another Japanese retrospective case–control study, including 49 
singleton pregnancies complicated by adenomyosis and 245 controls, showed that patients with 
adenomyosis have increased risks of second-trimester miscarriage, pre-eclampsia, placental 
malposition and preterm delivery (21). 
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Strengths and limitations 
This study has some limitations. First, it is a retrospective study, although the data were collected 
prospectively. Second, the sample size was relatively small, especially in the subgroup analysis. The 
small number of pregnant women with endometriosis and adenomyosis did not allow further 
subanalysis to be performed according to the type of endometriosis diagnosed by ultrasonography 
(i.e. ovarian endometriomas or DIE). However, these preliminary findings may pave the way for 
future studies with a larger sample size. Finally, we did not exclude patients who conceived by 
assisted reproductive technology, and this could be a potential bias on the prevalence of adverse 
pregnancy outcome, such as pre-eclampsia, even though the number of these conceptions was 
quite small and similar between the study groups. The main strength of this study is that the 
subgroups of women with diffuse adenomyosis and those with focal adenomyosis were considered 
separately when compared with those with endometriosis only, allowing a clear understanding of 
the role of the different forms of adenomyosis in the development of adverse pregnancy outcome.  
 
Conclusions 
In conclusion, the current study shows that diffuse adenomyosis in pregnant women with 
endometriosis is strongly associated with delivery of a SGA infant. Women with endometriosis and 
diffuse adenomyosis should be treated as being at high risk of placental dysfunction and might need 
closer monitoring during pregnancy. These results are also potentially useful for preconception and 
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CHAPTER 5 STUDY 2:  
Impact of Endometriomas and Deep Infiltrating Endometriosis on 
Pregnancy Outcomes and on First and Second Trimester Markers 
of Impaired Placentation 
 
INTRODUCTION 
Endometriosis is a chronic estrogen-dependent gynecologic disorder affecting at least 3.6% of 
women of reproductive age (1). Pro-inflammatory alterations of both peritoneal cavity and eutopic 
endometrium have been demonstrated in patients with this hormone-dependent chronic disease, 
who often suffer from pain symptoms and infertility (2). Eutopic endometrium and inner 
myometrium of these women have been demonstrated to have structural and functional 
abnormalities, not only due to the abnormal expression of genes that are critical for locally 
producing estrogens and responding to progesterone, but also to alteration of oxidative stress 
response, presence of inflammatory mediators, cytokines, and various apoptotic markers (3–5).Due 
to these abnormalities, endometriosis has been associated with defective deep placentation and 
several obstetrics adverse outcomes (6). In the literature, several studies reported a correlation 
between his benign chronic disease and higher risk of spontaneous late abortion (7), preterm 
premature rupture of the membranes and preterm birth (8–14), small for gestational age (SGA) (8–
14), pregnancy-induced hypertension (12) and pre-eclampsia (8,11), gestational diabetes (13), and 
placenta previa (8–10,12,14),and other obstetric hemorrhages (such as abruptio placentae and 
postpartum bleeding) (11,13,14) have been reported for these patients. However, some other 
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studies (15,16) did not definitively confirm the higher risk some of these major obstetric adverse 
outcomes; thus, this topic remains controversial (17). 
Our academic group recently demonstrated that the presence of di 
use adenomyosis in women with endometriosis was more strongly associated with impaired 
placentation and delivery of SGA infants in comparison to patients with only endometriosis and with 
focal adenomyosis and concomitant endometriosis (18); notably, these data may suggest a potential 
major role of adenomyosis in enhancing the risk of having these obstetrics adverse outcomes. 
However, despite this background, the role of each endometriotic phenotypes, in particular ovarian 
endometrioma (OE) and deep endometriosis (DE), as specific risk factor for developing adverse 
perinatal outcomes in women with endometriosis, has been not yet investigated. This study aimed 
to investigate if perinatal and maternal outcomes, particularly with regard to prevalence of SGA 
infants, are different in pregnant women with OE versus those with DE without OE. 
 
MATERIALS AND METHODS 
Study Design and Population 
This study was done by performing a retrospective analysis of a prospective database collected 
between January 2017 and June 2018. Women included in the study signed a general consent form 
for using their clinical data for scientific purposes. The research on humans has been performed by 
respecting of all the relevant national regulations and institutional policies, in accord to the tenets 
of the Helsinki Declaration. This study was approved by the Regional Ethic Committee (372REG2017; 
approval 12 Jan 2018). 
Pregnant women with ultrasonographic diagnosis of endometriosis prior to conception were 
included. The ultrasonographic assessment was performed at any phase of the menstrual cycle 
regardless of the administration of hormonal treatment (estroprogestins and progestins). 
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Standardized ultrasonographic criteria were employed for the diagnosis of DE (19) and OE (20); in 
particular, women with rectosigmoid endometriosis underwent a detailed assessment of intestinal 
symptoms and a rectal water contrast transvaginal ultrasonography in order to estimate the risk of 
sub occlusion prior to trying to spontaneously conceive (21,22). 
The patients were divided into three groups: women with OE, women with DE without OE, and 
women without endometriosis (controls). The controls were matched on the basis of age and parity. 
The controls were selected as the first patient who delivered at our institution, had no prior 
diagnosis of endometriosis and no symptoms suggestive of this disease (defined as presence of 
dysmenorrhea, deep dyspareunia, and/or chronic pelvic pain that require analgesic therapy), and 
had the same range of age of the cases with endometriosis (defined as 18–25, 26–30, 31–35, 35–
40, and >41 years old). 
Women with previous ultrasonographic diagnosis of uterine adenomyosis (23), with chronic 
hypertension disease, previous uterine surgery or malformations, and known autoimmune diseases 
were excluded. Previous surgery for endometriosis was not considered an exclusion criterion for the 
study if, after surgery, the presence of persistent or recurrent endometriosis was demonstrated at 
the ultrasonographic assessment. Moreover, pregnancies characterized by major fetal structural 
abnormalities and/or fetal aneuploidy, obtained by assisted reproductive techniques (ART) and 
multiple gestations were excluded. 
 In the first pregnancy-trimester, the measure of crown–rump length (CRL) was used for dating 
pregnancies according to the NICE (National Institute for Health and Clinical Excellence) guidelines 
(24). 
At the time of 11–14 weeks of pregnancy, PAPP-A levels were measured as first-trimester combined 
screening test for Down syndrome. Both at the time of routine ultrasonography at 11–14 weeks and 
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of routine anomaly abdominal ultrasonography at 19–23 weeks of pregnancy, uterine artery (UtA) 
Doppler indices were evaluated; pulsatility index (PI) of the left and the right UtA was averaged to 
obtain mean PI, which was plotted against a published reference range (25). During the routine 
anomaly scan, cervical length was measured by transvaginal ultrasonography following standard 
parameters: a short cervix was defined if characterized by length 25 mm (26); the suggestion of daily 
use of vaginal progesterone (200 mg, micronized progesterone capsules) and bed rest were given 
to women with short cervix in order to prevent preterm birth, according to our institution protocol. 
During the third pregnancy trimester, at 29–34 weeks, an ultrasonographic scan was done in all the 
patients to evaluate fetus growth. The administration of aspirin at low-doses as prevention for 
preeclampsia was not allowed during the study period. 
GE Voluson E6 (GE Healthcare, Zipf, Austria) was employed for all the ultrasonographic assessments. 
At the first study visit, baseline maternal characteristics, including age, ethnic origin, and body mass 
index (BMI) were recorded. The maternal and neonatal outcomes of each pregnancy were collected. 
Delivery or follow-up scans were arranged as appropriate for any suboptimal assessments. 
Gestational complications were defined with standardized criteria: pregnancy induced hypertension 
(PIH), detecting after 20 gestation weeks a blood pressure persistently over 140/90 mmHg in a 
woman with previously normal pressure values; preeclampsia, in case of gestational hypertension 
and concomitant proteinuria (>300 mg/24 h); preterm birth, indicating a delivery before the 
completion of 37 gestation weeks; and SGA, in case of an infant with birth weight less than the 10th 
centile for gestational age. 
 
Statistical Analysis 
The Kolmogorov–Smirnov test of normality was used for assessing the distribution of data, which 
were expressed as mean (SD), or median and interquartile range as appropriate. Categorical 
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variables were described as number (%). The correlations between continuous variables were 
evaluated by Pearson coefficient or by Spearman rho and those between categorical variables were 
evaluated by Pearson x2 test. Continuous variables were compared by Mann–Whitney and 
independent t-tests. 
Mean UtA Doppler PI, estimated fetal weight (EFW) centiles, and z-scores were calculated by using 
appropriate previously described reference ranges (24). Mean UtA Doppler PI was corrected for 
gestational age; multiple of medians were calculated by using the reference ranges extracted from 
the published centiles (24). Logistic regression analysis was used to evaluate the association 
between maternal characteristics, first- and second-trimester markers, and fetal outcomes for 
women with OE and DE without OE; P < 0.05 was considered statistically significant. Appropriate 
statistical software (SPSS 20.0; SPSS Inc, Chicago, IL) was employed for the statistical data analysis. 
 
RESULTS 





























Table 1. Comparison between pregnant women with ovarian endometriomas and deep 
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30.3 (27.0-33.0) 0.933 0.882 
Nulliparous (n, %) 34 (85.0) 35 (87.5) 69 (86.2) 0.849 0.853 





25.1 (21.5-26.7) 0.152 0.763 































Previous early miscarriage (n, %) 2 (5.0) 2 (5.0) 4 (5.0) 1.000 1.000 
Smoking (n, %) 5 (12.5) 5 (12.5) 18 (22.5) 0.190 0.190 
Surgical/histological diagnosis of disease (n, %) 
• Rectovaginal, (n, %) 
• Colorectal, (n, %) 
• Uterosacral, (n, %) 



























1st and 2nd trimester variables  





1.09 (0.66-1.55) 0.411 0.502 





1.01(0.56-1.36) 0.384 0.205 





1.64 (1.28-1.98) 0.590 0.806 
Mean UtA PI 1st trimester z-scores (mean, SD) - 0.09  1.37 0.031.59 -0.15 1.58 0.553 0.850 





0.96 (0.75-1.13) 0.591 0.733 
Mean UtA PI 2st trimester z-scores (mean, SD) 0.08  0.61 -0.09  1.02 0.09  0.87 0.322 0.561 
Short cervix (<25mm) 0 (0) 1 (2.5) 1 (0.8) 0.614 0.478 
Scan assessment during the 3rd trimester of pregnancy  





31.7 (30.5-33.2) 0.896 0.965 
EFW (g, mean, SD) 1868 (±291) 1944 (284) 1895  (287) 0.389 0.200 
EFW centile (mean, SD) 51.0 (±31.0) 56.6 (32.6) 53.3 (31.8) 0.593 0.296 
SGA fetuses (n, %) 10 (8.3) 3 (7.5) 7 (8.8) 0.815 0.815 
Pregnancy and perinatal outcome  





39.0 (38.1-40.5) 0.934 0.806 
Birth Weight (mean, SD) 3334 (±495) 3368 ( 497) 3337 (515) 0.754 0.922 
Birth weight (centile, mean, SD) 50.0 (±27.9) 52.7 ( 28.4) 50.9 (29.2) 0.744 0.655 
SGA (n, %) 10 (8.3) 3 (7.5) 8 (10.0) 0.655 0.350 
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Data are shown as median (interquartile range) or number (%). 
Endo: Endometriosis; Deep infiltrating endometriosis: DE; Ovarian endometrioma: OE; Body Mass Index: BMI; pregnancy-associated 
plasma protein A: PAPP-A; beta human chorionic gonadotropin: BhCG; estimated fetal weight: EWF; small for gestational age: SGA; 





There was no statistically significant difference in the baseline data within the three study groups. 
Overall, 160 pregnant women had complete follow-up, as required for being eligible for the study 
analysis; within this population, 40 (25%) had OE, 40 (25%) had DE, and 80 (50%) had no 
endometriosis. 
A statistically significant difference was not observed in the first trimester levels of PAPP-A, first 
trimester and mid-pregnancy mean UtA Doppler PI, EFW centile, and prevalence of SGA fetuses 
between patients presenting with OE and healthy women; moreover, no statistically significant 
difference was found in the prevalence of preeclampsia, SGA infants, and five-minute Apgar score 
between these two groups (Table 1). Moreover, a statistically significant difference was not 
observed in the first trimester levels of PAPP-A, first trimester and mid-pregnancy mean UtA 
Doppler PI, EFW centile, and prevalence of SGA infants between patients presenting with DE 
without OE and healthy women. No statistically significant difference was again found in the 
prevalence of preeclampsia, SGA infants, and five-minute Apgar score between these two groups 
(Table 1). The correlation between maternal and pregnancy specific characteristics with SGA and OE 
and DE was done by logistic regression analysis; Table 2 reports the data related to this analysis. 
Either the presence of OE nor that of DE without OE were found independently associated with 
delivering SGA infants (Figure 1). 
 
5-minute Apgar <7 (n, %) 5 (4.1) 2 (5.0) 4 (5.0) 1.000 0.518 
Preeclampsia (n, %) 9 (7.5) 4 (10.0) 6 (7.5) 0.640 1.000 
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Table 2. Logistic regression analysis for prediction of SGA 
 
SGA (n) OR 95% CI p-value 
Maternal age 1.038 0.893-1.207 0.628 
BMI  0.977 0.868-1.100 0.704 
PAPP-A (MoM) 0.842 0.309-2.296 0.737 
UtA mean PI (2nd trimester) 0.359 0.036-3.579 0.383 
OE 1.489 0.366-6.067 0.578 
DE 2.121 0.426-10.564 0.381 
Deep infiltrating endometriosis: DE; Ovarian endometrioma: OE; Body Mass Index: BMI; beta human chorionic 
gonadotropin: BhCG; pregnancy-associated plasma protein A: PAPP-A; Uterine artery: UtA; Pulsatility index: PI; small 
for gestational age: SGA 
 
 
Figure 1. Odds ratios with 95% CIs for delivering SGA infants in women with ovarian endometriomas (OE) and deep 




The results obtained from this study demonstrate that the presence of OE or DE in pregnant women 
is not associated with an increased risk of delivering SGA infants. During the scan assessment in the 
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3rd trimester of pregnancy, the prevalence of SGA infants was similar within the three study groups 
(OE: 8.3%; DE: 7.5%; healthy women: 8.8%); similar results were observed for the prevalence of SGA 
infants at birth (OE: 8.3%; DE: 7.5%; healthy women: 10.0%). When assessed singularly, 
conventional risk factors for placental insufficiency, such as BMI, PAPP-A, and mean UtA Doppler PI 
in first and the second trimesters of pregnancy, did not demonstrate a significant correlation with 
the presence of OE or DE. More importantly, logistic regression analysis showed that either the 
presence of OE (1.489; 95 CI % 0.366–6.067; p = 0.578) nor the presence of DE (2.121; 95 CI % 0.426–
10.564; p = 0.381) were associated with the occurrence of SGA infants, after adjusting the results 
for potential confounding variables (maternal age, ethnicity, BMI, PAPP-A, and mean UtA Doppler 
PI). Thus, these data seem to not support a potential causative link between these endometriotic 
phenotypes and impaired placentation and subsequent development of SGA births. 
According to the existing literature, the relation between endometriosis and adverse obstetrics 
outcomes, such as preeclampsia and SGA, is still conflicting (11,27). Two recent systematic reviews 
with meta-analysis tried to summarize evidence on this topic (28,29). In both, subgroup analyses for 
spontaneous and assisted conception were attempted in order to remove the confounding factor 
represented by assisted reproduction. In general, women with endometriosis were found to have 
an increased risk of a range of obstetric and fetal complications, although results for specific adverse 
maternal and neonatal outcomes tended to differ between these two reviews. Specifically, none of 
the two (30) reported a pooled increased risk for delivering SGA infants in patients affected by 
endometriosis; only one (30) observed an increased risk of developing PIH. However, evidence from 
the analysis of data is limited by the quality and heterogeneity of the studies included: for example, 
the diagnosis for endometriosis is not uniform; moreover, selection of control groups tends to differ 
across studies, with some studies evaluating fertile patients, sub fertile patients, or patients a 
affected by male factor infertility as non-endometriotic controls. 
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A not negligible number of recent studies have found both lower and unchanged risks for these 
outcomes. Hadfield et al. evaluated 208,879 women with a singleton first birth in the period 2000–
2005 in the Australian state of New South Wales in a large population study; among them, 3239 had 
an earlier diagnosis of endometriosis. No association between the presence of endometriosis and 
pregnancy-induced hypertension or preeclampsia was reported in this study (30); notably, 
stratification for ART did not change the results. In another observational study, Benaglia et al. 
reported an unchanged risk of hypertensive disorders, preterm birth, gestational diabetes, SGA and 
large for gestational age newborns, and neonatal problems in women affected by endometriosis 
(15). Otherwise, Stephansson et al., in a large cohort of women affected by this chronic benign 
disease, found an increased risk of pre-eclampsia, preterm birth, antepartum bleeding/placental 
complications, and cesarean section, but any statistically significant association with SGA infants or 
stillbirth was not found (14). 
Recently, our academic group demonstrated that the presence of di 
use adenomyosis in pregnant women affected by endometriosis is strongly associated with SGA 
infants, thus suggesting a causative relationship between di 
use adenomyosis and placental dysfunction (18). 
The current study investigated, for the first time in the literature, the influence of OE and DE without 
OE on adverse pregnancy outcomes in women who conceived spontaneously, revealing that neither 
the presence of OE nor that of DE alone should not be considered relevant risk factors for placental 
impairment and consequently delivering SGA infants. This study is characterized by some 
limitations: firstly, its design is retrospective, although the data were prospectively collected. 
Furthermore, its sample size is relatively small and this could be considered an impediment for 
definite conclusions, especially when performing subgroup analysis. 
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However, the study population was highly selected, being composed of women with endometriosis 
who spontaneously conceived. Given that the main aim of the study was to give information for 
clinical practice, we were interested in associations of relevant size; in the near future, these 
preliminary findings may pave the way for trials with larger sample sizes. A further limitation of the 
current study is that the presence of specific localizations of endometriosis was assessed before 
conception by ultrasonography. Ideally, a diagnostic laparoscopy before conception would provide 
a better assessment of the disease but obviously, it is not ethically acceptable to perform a surgical 
procedure only for this purpose; anyway, because of this study design, we were not able to 
determinate whether some patients with OE had small DE lesions (main diameter less than 1 cm) 
not detected by ultrasonography; in contrast, it seems unlikely that OEs were not diagnosed by 
ultrasonography in the DE group. Similarly, the presence of superficial peritoneal endometriosis in 
the control group cannot be excluded. However, considering that endometriosis has a low 
prevalence (about 4%) in the general population (1) and that the control patients did not have pain 
symptoms requiring antalgic therapy prior to conception, it seems unlikely that a relevant 
percentage of control women had undiagnosed endometriosis. 
A strength of this observational study is that patients with OE and DE without OE were separately 
studied in subgroups and compared to women without endometriosis; this has been done in order 
to better understand the impact of each phenotype of endometriosis on specific adverse pregnancy 
outcomes, and in particular on delivering SGA infants. Moreover, patients who conceived by ART 
procedures were excluded, thus eliminating the potential bias related to higher prevalence of 






The current study shows that the presence of OE and DE without OE are not risk factors of delivering 
an SGA infant. Thus, patients affected by endometriosis should be treated during pregnancy as the 























1. Ferrero, S.; Arena, E.; Morando, A.; Remorgida, V. Prevalence of newly diagnosed endometriosis in women attending 
the general practitioner. Int. J. Gynaecol. Obstet. 2010, 110, 203–207.  
 
2. Eskenazi, B.; Warner, M.L. Epidemiology of endometriosis. Obstet. Gynecol. Clin. North Am. 1997, 24, 235–258.  
 
3. Brosens, I.; Kunz, G.; Benagiano, G. Is adenomyosis the neglected phenotype of an endomyometrial dysfunction 
syndrome? Gynecol. Surg. 2012, 9, 131–137.  
 
4. Petraglia, F.; Arcuri, F.; de Ziegler, D.; Chapron, C. Inflammation: A link between endometriosis and preterm birth. 
Fertil. Steril. 2012, 98, 36–40.  
 
5. Benagiano, G.; Brosens, G.; Habiba, M. Structural and molecular features of the endomyometrium in endometriosis 
and adenomyosis. Hum. Reprod. Update 2014, 20, 386–402.  
 
6. Brosens, I.; Pijnenborg, R.; Vercruysse, L.; Romero, R. The “Great Obstetrical Syndromes” are associated with 
disorders of deep placentation. Am. J. Obstet. Gynecol. 2011, 204, 193–201.  
 
7. Aris, A. A 12-year cohort study on adverse pregnancy outcomes in Eastern Townships of Canada: Impact of 
endometriosis. Gynecol. Endocrinol. 2014, 30, 34–37.  
 
8. Berlac, J.F.; Hartwell, D.; Skovlund, C.W.; Langho_-Roos, J.; Lidegaard, O. Endometriosis increases the risk of 
obstetrical and neonatal complications. Acta Obstet. Gynecol. Scand. 2017, 96, 751–760.  
 
9. Harada, T.; Taniguchi, F.; Onishi, K.; Kurozawa, Y.; Hayashi, K.; Harada, T.; Japan Environment & Children’s Study 
Group. Obstetrical Complications in Women with Endometriosis: A Cohort Study in Japan. PLoS ONE 2016, 11, 
e0168476. 
 
10. Mannini, L.; Sorbi, F.; Noci, I.; Ghizzoni, V.; Perelli, F.; Di Tommaso, M.; Mattei, A.; Fambrini, M. New adverse 
obstetrics outcomes associated with endometriosis: A retrospective cohort study. Arch. Gynecol. Obstet. 2017, 295, 
141–151.  
 
11. Glavind, M.T.; Forman, A.; Arendt, L.H.; Nielsen, K.; Henriksen, T.B. Endometriosis and pregnancy 
complications: A Danish cohort study. Fertil. Steril. 2017, 107, 160–166.  
 
12. Exacoustos, C.; Lauriola, I.; Lazzeri, L.; De Felice, G.; Zupi, E. Complications during pregnancy and delivery in women 
with untreated rectovaginal deep infiltrating endometriosis. Fertil. Steril. 2016, 106, 1129–1135.e1121. 13. Conti, N.; 
Cevenini, G.; Vannuccini, S.; Orlandini, C.; Valensise, H.; Gervasi, M.T.; Ghezzi, F.; Di Tommaso, M.; Severi, F.M.; Petraglia, 
 65 
F.Women with endometriosis at first pregnancy have an increased risk of adverse obstetric outcome. J. Matern. Fetal 
Neonatal Med. 2015, 28, 1795–1798.  
 
14. Stephansson, O.; Kieler, H.; Granath, F.; Falconer, H. Endometriosis, assisted reproduction technology, and risk of 
adverse pregnancy outcome. Hum. Reprod. 2009, 24, 2341–2347. 
 
15. Benaglia, L.; Candotti, G.; Papaleo, E.; Pagliardini, L.; Leonardi, M.; Reschini, M.; Quaranta, L.; Munaretto, M.; Viganò, 
P.; Candiani, M.; et al. Pregnancy outcome in women with endometriosis achieving pregnancy with IVF. Hum. Reprod. 
2016, 31, 2730–2736.  
 
16. Mekaru, K.; Masamoto, H.; Sugiyama, H.; Asato, K.; Heshiki, C.; Kinjyo, T.; Aoki, Y. Endometriosis and pregnancy 
outcome: Are pregnancies complicated by endometriosis a high-risk group? Eur. J. Obstet. Gynecol. Reprod. Biol. 2014, 
172, 36–39.  
 
17. Leone Roberti Maggiore, U.; Ferrero, S.; Mangili, G.; Bergamini, A.; Inversetti, A.; Giorgione, V.; Viganò, P.; Candiani, 
M. A systematic review on endometriosis during pregnancy: Diagnosis, misdiagnosis, complications and outcomes. 
Hum. Reprod. Update 2016, 22, 70–103.  
 
18. Scala, C.; Leone Roberti Maggiore, U.; Racca, A.; Barra, F.; Vellone, V.G.; Venturini, P.L.; Ferrero, S. Influence of 
adenomyosis on pregnancy and perinatal outcomes in women with endometriosis. Ultrasound Obstet. Gynecol. 2017, 
52, 666–671.  
 
19. Guerriero, S.; Condous, G.; van den Bosch, T.; Valentin, L.; Leone, F.P.; Van Schoubroeck, D.; Exacoustos, C.; Installé, 
A.J.; Martins,W.P.; Abrao, M.S.; et al. Systematic approach to sonographic evaluation of the pelvis in women with 
suspected endometriosis, including terms, definitions and measurements: A consensus opinion from the International 
Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstet. Gynecol. 2016, 48, 318–332.  
 
20. Van Holsbeke, C.; Van Calster, B.; Guerriero, S.; Savelli, L.; Paladini, D.; Lissoni, A.A.; Czekierdowski, A.; Fischerova, 
D.; Zhang, J.; Mestdagh, G. Endometriomas: Their ultrasound characteristics. Ultrasound Obste. Gynecol. 2010, 35, 730–
740.  
 
21. Menada, M.V.; Remorgida, V.; Abbamonte, L.H.; Fulcheri, E.; Ragni, N.; Ferrero, S. Transvaginal ultrasonography 
combined with water-contrast in the rectum in the diagnosis of rectovaginal endometriosis infiltrating the bowel. Fertil. 
Steril. 2008, 89, 699–700.  
 
22. Valenzano Menada, M.; Remorgida, V.; Abbamonte, L.H.; Nicoletti, A.; Ragni, N.; Ferrero, S. Does transvaginal 
ultrasonography combined with water-contrast in the rectum aid in the diagnosis of rectovaginal endometriosis 
infiltrating the bowel? Hum. Reprod. 2008, 23, 1069–1075.  
 
 66 
23. Van den Bosch, T.; Dueholm, M.; Leone, F.P.; Valentin, L.; Rasmussen, C.K.; Votino, A.; Van Schoubroeck, D.; Landolfo, 
C.; Installé, A.J.; Guerriero, S.; et al. Terms, definitions and measurements to describe sonographic features of 
myometrium and uterine masses: A consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) 
group. Ultrasound Obstet. Gynecol. 2015, 46, 284–298 
 
24. National Collaborating Center forWomen’s and Children’s Health (UK). Antenatal care: Routine care for the healthy 
pregnant woman. In NICE Clinical Guidelines, No. 62; National Institute for Health and Clinical Excellence: London, UK, 
2008. 
 
25. Gómez, O.; Figueras, F.; Fernández, S.; Bennasar, M.; Martínez, J.M.; Puerto, B.; Gratacós, E. Reference ranges for 
uterine artery mean pulsatility index at 11–41 weeks of gestation. Ultrasound Obstet. Gynecol. 2008, 32,128–132.  
 
26. Berghella, V.; Baxter, J.K.; Hendrix, N.W. Cervical assessment by ultrasound for preventing preterm delivery. 
Cochrane Database Syst. Rev. 2013, CD007235.  
 
27. Leone Roberti Maggiore, U.; Inversetti, A.; Schimberni, M.; Viganò, P.; Giorgione, V.; Candiani, M. Obstetrical 
complications of endometriosis, particularly deep endometriosis. Fertil Steril. 2017, 108, 895–912.  
 
28. Horton, J.; Sterrenburg, M.; Lane, S.; Maheshwari, A.; Li, T.C.; Cheong, Y. Reproductive, obstetric, and perinatal 
outcomes of women with adenomyosis and endometriosis: A systematic review and meta-analysis. Hum. Reprod. 
Update 2019.  
 
29. Lalani, S.; Choudhry, A.J.; Firth, B.; Bacal, V.; Walker, M.; Wen, S.W.; Singh, S.; Amath, A.; Hodge, M.; Chen, I. 
Endometriosis and adverse maternal, fetal and neonatal outcomes, a systematic review and meta-analysis. Hum. 
Reprod. 2018, 33, 1854–1865. 
 
30. Hadfield, R.M.; Lain, S.J.; Raynes-Greenow, C.H.; Morris, J.M.; Roberts, C.L. Is there an association between 













CHAPTER 6 CLASSIFICATION OF FGR 
 
Normal fetal growth reflects the interaction between genetically pre-determined growth potential 
and fetal, placental, and maternal health. Normal fetal growth has a primary phase of cellular 
hyperplasia in the first 16 weeks of the pregnancy. Between 16 and 32 weeks, there is a concomitant 
phase of hyperplasia and cellular hypertrophy, with an increase in the number and size of cells. From 
week 32, there is a cellular hypertrophy phase, with a rapid increase in cell size. This pattern of 
normal fetal growth is the basis for the clinical classification of FGR. 
Campbell (1) used the head circumference/abdominal circumference (HC/AC) ratio to differentiate 
between symmetrical or harmonic small fetuses and asymmetrical fetuses, i.e., those with a 
disproportionately slower growth of AC, and classified FGR into types I, II, and III. 
Type I: this type include FGR fetuses with a symmetrical harmonic restricted growth, defined by a 
reduced intrinsic potential of growth. These fetuses shows a proportional decrease in the size of 
both head and abdomen circumference. Etiological factors affect the growth pattern of these 
fetuses at an early stage, during the cellular hyperplasia phase. 
Type II: this type is characterized by a late onset of drop in growth, after 30 or 32 weeks, in the 
cellular hypertrophy phase, generally resulting in asymmetry and disharmony. HC and FL are less 
affected, corresponding to the gestational age. However, AC is commonly most seriously affected, 
decreasing the estimated fetal weight. The main etiological factor of asymmetric FGR is placental 
insufficiency. 
Type III: this type results from an association of the previous two mechanisms (types I and II). The 
change occurs in the second trimester, which is when the hyperplasia and hypertrophy phases 
occur. Since the changes occurs at a relatively early stage of pregnancy, the fetuses show semi 
harmonious growth with a hypotrophic appearance. It is usually due to embryonic infections such 
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as those caused by rubella virus, cytomegalovirus, and Toxoplasma gondii as well as with toxic 
agents that affect the fetus, such as pharmaceuticals, illegal drugs, and toxins. 
Nowadays, the chronological classification of FGR, which is based on the time of onset, is the most 
commonly used classification. This new classification has a better clinical applicability helping 
clinician in the management of the FGR fetuses. Figueras and Gratacós (2) and Baschat (3) have 
reported different pathophysiological behaviors in fetuses with FGR before and after 32 weeks. 
Fetuses with early FGR (<32 weeks) showed a substantial change in placental implantation, which 
often leads to increased resistance in the uterine artery and an increased risk of developing PIH and 
preeclampsia. For this reason, the risk of fetal hypoxia is higher and fetuses usually present 
cardiovascular adaptation. Perinatal morbidity and mortality rates are high. In late-onset FGR (≥32 
weeks), there are slight placentation deficiencies that lead to mild hypoxia and require little 
cardiovascular adaptation by the fetus. However, the degree of tolerance to hypoxia is low; in 
contrast to cases of early onset FGR, the fetus are not able to tolerate this low oxygen supply for 
long. The major challenge in early onset FGR is management, while the problem associated with 
late-onset FGR is early diagnosis, because the umbilical artery Doppler findings may still be normal, 
thereby masking the disease.  
In 2016, has been proposed the Delphi procedure to define, classify and diagnose FGR fetuses (4). 
During this consensus the 32nd week of gestation was defined as the cut-off point for early versus 
late-onset FGR classification, and fetuses with congenital anomalies were excluded from this 
classification. Thus, in early onset FGR, the estimated fetal weight and/or AC is less than the third 
percentile or the umbilical artery Doppler which shows absent and/or zero diastolic flow. Early onset 
FGR can also be classified and diagnosed when two of the following three parameters are present: 
(1) estimated fetal weight and/or AC < the tenth percentile, (2) pulsatility index (PI) of the uterine 
artery > the 95th percentile, and (3) PI of the umbilical artery > the 95th percentile. Late-onset FGR 
 69 
is determined by only one parameter: estimated fetal weight and/or AC < the third percentile. Late-
onset FGR can also be classified and diagnosed when two of the following three parameters are 
present: (1) estimated fetal weight and/or AC < the tenth percentile, (2) fetal growth two “quartiles” 
lower during fetus monitoring, and (3) cerebroplacental ratio (CPR) < the fifth percentile. Doppler 
follow-up of the umbilical artery has a major importance in early onset FGR. In cases of late-onset 
FGR, umbilical artery Doppler can be normal or only become abnormal in advanced stages of the 
disease. In late-onset FGR, placental dysfunction is less severe and we can observe decreasing of 
middle cerebral artery Doppler and cerebral placental ratio (CPR) with normal or minimal uterine 
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CHAPTER 7 DOPPLER VELOCIMETRY 
 
The Doppler velocimetry assessment enables the non-invasive detection of signs of placental 
insufficiency and of fetal hemodynamic changes that occur during fetal cardiovascular adaptation. 
The Doppler velocimetry assessment can be performed using the uterine arteries (maternal 
circulation), umbilical arteries (feto-placental circulation), and other fetal vessels [cerebral artery, 
abdominal aorta, renal artery, ductus venosus (DV), and transverse sinus]. This analysis is 
fundamental to identify restricted fetuses at risk of hypoxia, which occurs in approximately 40% of 
cases (1). Moreover, it is helpful to make a differential diagnosis of pathological restrictions, i.e., 
between fetuses that are deficient in nutrients or have hypoxia and require intensive management 
and those that are constitutionally small, in which case, a more conservative treatment can be 
adopted.  
 
CHAPTER 7.1 Uterine artery Doppler 
 
The uterine artery Doppler evaluation plays a key role in the diagnosis of abnormal placentation. It 
has been assessed in a previous study the role of uterine artery evaluation between 11 and 14 
weeks, particularly for the prediction of pre-eclampsia,  usually associated with early onset FGR. The 
authors used the mean PI uterine artery Doppler as parameter using a cutoff >2.35 (sensitivity for 
isolated prediction of FGR and needed for delivery <32 weeks due FGR of 11.7 and 27.8%, 
respectively) (2). It can also be re-evaluated during the second trimester, because it identifies 
pregnancies with a risk of placental failure, pre-eclampsia, and SGA through increased resistance 
(mean PI uterine artery > 95th centile) with or without the presence of unilateral or bilateral 
diastolic notch (3).  
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A recent consensus established the importance of fetal evaluation using a uterine artery Doppler, 
particularly in cases of early onset FGR. PI of the uterine arteries > the 95th percentile associated 
with estimated fetal weight or with AC < the 10th percentile represents a sufficient parameter for 
FGR diagnosis (4). 
 
CHAPTER 7.2 Umbilical artery, medial cerebral artery, and fetal hemodynamic 
centralization 
 
The umbilical artery Doppler reflects placental vascular resistance, which is strongly correlated with 
placental impairment. In a normally grown fetus, umbilical artery resistance gradually decreases 
during pregnancy, while in case of FGR, particularly in early onset FGR, the reverse occurs (5). The 
reduction in placental flow is the first hemodynamic signal of a placental lesion, with impaired villi 
microcirculation (6). Thus, placental lesions are associated with a decrease in umbilical artery 
perfusion, increasing PI and RI uterine artery Doppler values (Figure METTI IMMAGINI DOPPLER 
PATOLOGICO).  
The next step in fetal deterioration in response to placental insufficiency is the hemodynamic 
centralization. During hypoxemia, there is selective vasodilation to preserve major organs, 
particularly brain, heart, and adrenals glands and a contemporaneous vasoconstriction in other 
organs (the kidney, lung, intestine, skin, and bones) (7).  
Thus, the fetal hemodynamic centralization process worsens umbilical artery PI, with a loss of its 
diastolic component until it becomes inverse, in addition to increasing the resistance in the distal 
thoracic aorta with a higher PI.  
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Next, the ratio between PI of the middle cerebral artery and the umbilical artery becomes 
progressively smaller because of cerebral vasodilation, determined by the decrease in PI of the 
medial cerebral artery. 
Ductus venosus (DV) plays an fundamental role in delaying the fetal hemodynamic centralization 
process by redirecting a significant amount of blood flow from the fetal liver to the heart, thereby 
ensuring more blood flow to the heart and brain (8).  
The increase in DV flow is allowed by two factors: the existence of innervation and that of 
musculature in the anastomosis of the umbilical vein in the hepatic portal system, leading to the 
enlargement of DV and increase in resistance in the right hepatic vein (9).  
It has been observed that the occurrence of decelerations in antepartum cardiotocography has a 2-
week delay between the onset of fetal hemodynamic centralization. Therefore, it can be concluded 
that Doppler abnormalities precede changes in the biophysical profile.  
The disappearance of the diastolic component on the umbilical artery Doppler coincides with 
changes in the acid–base balance (10, 11). Perinatal mortality is higher in this group, with several 
neonatal complications due to vasoconstriction in several organs (10). 
Preceding fetal death, there is generalized vasoplegia and irreversible hemodynamic changes, a 
period referred to as flow decentralization (12). Cerebral edema is the result of the accumulation of 
lactic acid during the period of hypoxia and anaerobic respiration, altering cell membrane 
permeability and increasing intracellular osmotic pressure with the appearance of necrosis and 
edema (13). Because of edema, difficulty in cerebral perfusion occurs, with the appearance of highly 
resistant flow rate waves on the Doppler of the medial cerebral arteries, even without the diastolic 
component. Concomitantly, changes in the umbilical area persist, and in some cases, a false 
normalization of this area may occur, while persistent changes in the venous system persist. 
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CHAPTER 7.3 CPR 
 
CPR, calculated as the product of PI of the medial cerebral artery and PI of the umbilical artery is 
another tool to assist assessment and management of FGR. Abnormal CPR has recently been 
associated with adverse perinatal outcomes, higher admission rates in intensive care units (NICUs), 
post-natal neurological deficits, and lower Apgar scores.  
Recently DeVore (14) reviewed several studies in which CPR was assessed in both normal and SGA 
fetuses to determine whether the test should be conducted in clinical practice. What has been 
found was that an abnormal CPR was a better predictor of adverse events than the biophysical 
profile in cases of early onset FGR. Moreover, in normal for gestational age fetuses, an abnormal 
CPR could predict fetal distress during labor. 
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CHAPTER 8 STUDY 3:  
Mid pregnancy fetal growth, uteroplacental doppler indices and 




The birth of a stillborn infant is a devastating outcome of pregnancy and unfortunately is still a 
relatively common occurrence (1,2). Although several maternal and obstetric characteristics are 
associated with the risk of stillbirth, they explain less than 20% of the variance in the incidence of 
stillbirth and the major risk factor recognized for intrauterine death (IUD) is placental insufficiency 
(3-5). While two-thirds of stillbirths are “unexplained” by conventional classification, fetal growth 
restriction resulting from placental insufficiency is present in over half of these cases despite an 
apparently appropriate birthweight for gestational age (AGA) (6,7). Indeed, neonates defined as 
AGA may not have achieved their true growth potential leading to an incorrect classification that 
are likely to account for the group of stillbirth classified as unexplained on the basis of fetal size 
rather than Doppler criteria. Uterine artery (UtA) Doppler assessment has a strong association with 
impaired placental function (8) and several publications have reported the association of abnormal 
uterine artery Doppler indices both in the first and second trimester to stillbirth even when 
apparently unexplained (6,9-11). Several biophysical and biochemical tests performed during the 
first two trimesters of pregnancy have been proposed to predict stillbirth (5,9,11-13) but to date, 
there is still no clinically useful first or second- trimester test to predict IUD in unselected pregnant 
women. The aim of this study was to investigate the potential value of screening integrating mid-
pregnancy maternal demographics, fetal biometry and UtA pulsatility index (PI) in prediction of IUD 
and to examine the potential value of such assessment in identifying women who may benefit from 
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increased antenatal surveillance. The ability to predict stillbirths early in pregnancy and to offer 
additional surveillance and intervention to high-risk mother/fetus is understandably an important 
part of antenatal care. 
 
MATERIAL AND METHODS 
This was a retrospective cohort study of data obtained in a single maternity center over a 14-year 
period from 2000 to 2014. Inclusion criteria were: singleton pregnancy morphologically normal 
attending their routine scheduled ultrasound examination between 19 and 24 weeks of gestation. 
As a retrospective study of routinely collected data, ethics approval was not required (as for NHS-
REC). Secondly, the ethics committee approved the collection of pregnancy outcome data as part of 
the routine follow-up of FMU patients. Pregnancies complicated by fetal abnormality, maternal 
medical disorders, previous adverse obstetric outcome, aneuploidy or infection were excluded from 
the analysis. In addition, all patients that delivered elsewhere or referred from other hospitals were 
excluded from the study as it was not possible to obtain the postnatal outcomes. Gestational age 
(GA) was determined according to crown–rump length (CRL) in the first trimester (13). All the 
patients underwent a nuchal scan and double test as for the first trimester NHS protocol and only 
those classified as low risk have been included in the study. Data on ultrasound examinations were 
obtained from computerized records (Viewpoint software, General Electric, Wauwatosa, WI, USA) 
and only one (the anomaly scan) examination per fetus was included in the analysis. Ultrasound 
examinations were performed mainly with a Voluson GE (GE Medical Systems, Zipf Austria) 
ultrasound machine equipped with a 2-8 MHz convex probe. Qualified and experienced 
sonographers performed all scans. Maternal characteristics recorded included maternal age, body 
mass index, parity, ethnicity (Caucasian, Afro-caribbean, Asian and mixed), medical history and 
obstetric history. Data on pregnancy outcomes were collected from the hospital maternity records. 
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Ultrasound data, including head circumference, abdominal circumference and femur length (FL), 
were measured according to a standard protocol (15) and were converted to percentiles using 
reference values derived from low-risk pregnancies with documented normal outcome. 
Transabdominal color Doppler ultrasound was used to visualize the uterine arteries at the apparent 
crossover with the external iliac arteries (14). Measurements were taken with pulsed- wave Doppler 
at the lowest insonation angle achievable and when uniform waveforms with high signal to noise 
ratio were obtained the PI was measured. Maternal characteristics, second-trimester fetal biometry 
and Doppler measurements were compared between women who delivered stillborn and those 
who delivered live born babies. Maternal age, body mass index and all the ultrasound parameters 
were included as continuous variables; parity and ethnicity as nominal variables. 
Stillbirth was defined as the death of a fetus with a birthweight≥ 500 g or a gestational age >23+6 
weeks of gestation (1). We compared the potential value of maternal characteristics, fetal biometry 
and UtA Doppler indices in prediction of preterm and term stillbirths defining two groups: term 
stillbirth occurring > 37 weeks’ gestation and preterm stillbirth occurring at < 37 weeks’ gestation. 
Multivariate logistic regression analysis was used to estimate the association between second-
trimester ultrasound measurements and stillbirth and to determine the independence and relative 
contribution of variables. All variables significantly associated with stillbirth were included in the 
model. The risk for each of the pregnancy outcomes was then calculated from the formula: 
odds/(1+odds), where odds=eY, and Y was derived from the multivariate logistic regression analysis. 
The performance of screening was determined by receiver operating characteristic (ROC) curves. 






The study included 23,894 pregnancies that were scanned between 19 and 24 weeks’ gestation 
(Table 1). There were 90 stillbirths after 24 weeks’ gestation: 38 stillbirths occurred at term and 52 
were preterm. The results of the multivariate regression of the association between maternal 
characteristics and ultrasound parameters and the risk of stillbirth are shown in Table 2. Non- 
Caucasian ethnicity, FL centile and UtA PI were significantly associated with the risk of stillbirth (all 
p <0.01). The ROC curves of second trimester maternal demographics, fetal biometry and UtA 
Doppler parameters for predicting all, term and preterm stillbirths are presented in Figure 1 and 
Figure 2. The area under curve (AUC), the detection rates (DR) at a various false positive rates (FPR) 
of screening by maternal demographics, fetal biometry, UtA PI and their combination for stillbirth 
are given in Table 3. 
Screening by maternal demographics alone - at a 10% FPR – had a DR of 12% and 14% for term and 
preterm stillbirths, respectively. Screening combining maternal demographic characteristics, FL 
centile and UtA Doppler indices at the same FPR had a DR of 31 % for prediction for all stillbirths. In 
the term population, the DRs at 10% FPR were 27%, 24% and 27% using the combined parameters, 
UtA Doppler indices alone and FL centile in isolation, respectively. 
In addition, a sub-analysis was performed stratifying the results by Caucasian and non- Caucasian 
ethnicity (Supporting Information Table S1). No statistically significant differences were found 







Table 1 Baseline demographics of the study population . Data are given as mean ± SD or n (%). Small-for 
gestational age, SGA. 
 
Characteristic Population (=23804) Stillbirths (=90) P value 
Maternal age (years) 29.99 ± 5.6 30.6 ± 6.6 0.021 
BMI (kg/m2) 24.55 ± 4.8 25.24 ± 5.1 0.062 



















Gestation age at scan (weeks) 21.8 ± 0.6 21.9 ± 0.6 0.630 
Gestational age at delivery 
(weeks) 
39.7 ± 2 35.4 ± 4 0.000 
HC centile 58.81 ± 22.6 55.74 ± 24.1 0.146 
AC centile 59.42 ± 21.09 53.75 ± 25.37 0.003 
FL centile 59.83 ± 22.70 50.12 ± 27.46 0.001 
Ut A Doppler PI 0.875 ± 0.55 1.09 ± 0.72 0.000 
BW (g) 3295.6 ± 578 2508 ± 824 0.000 
Term delivery 22,241 (93.4%) 38 (42.2%) 0.000 
Preterm delivery <37 weeks  1,563 (6.6%) 52 (57.8%) 0.000 
Preterm delivery < 32 weeks 291 (1.2%) 25 (27.8%) 0.000 












Table 2. Results of the multivariate logistic regression analysis of factors associated with Stillbirth  
Maternal 
demographics, fetal 









BMI 1.027 1.021 0.98-1.10 0.189 






























AC centile 0.993 0.988 0.98-1.01 0.184 
FL centile 0.986 0.982 0.98-0.99 0.003 
HC centile 1.003 0.994 0.99-1.01 0.615 















Table 3. Performance of screening for all, term, preterm and very preterm stillbirths with maternal 
demographics, FL centile and UtA Dopplers. 
 
SCREENING TEST AUC DR at 10% 
FPR 
DR at 20% 
FPR 
DR at 30% 
FPR 
DR at 40% 
FPR 
All Stillbirths      
Maternal 
demographics 
0.568 19% 34% 45% 50% 
FL centile 0.601 26% 37% 47% 53% 
UtA Dopplers 0.693 28% 50% 62% 72% 
Mat demographics + 
FL+ UtA PI 
0.717 31% 46% 61% 72% 
Term Stillbirths      
Maternal 
demographics 
0.574 12% 19% 29% 36% 
FL centile 0.595 27% 37% 50% 53% 
UtA Dopplers 0.682 24% 45% 60% 74% 
Mat demographics + 
FL+ UtA PI 
0.714 27% 37% 47% 53% 
Preterm Stillbirths      
Maternal 
demographics 
0.556 14% 23% 38% 54% 
FL centile 0.615 23% 36% 44% 54% 
UtA Dopplers 0.705 31% 50% 62% 71% 
Mat demographics + 
FL+ UtA PI 
0.722 35% 44% 62% 75% 
Very preterm 
Stillbirths 
     
Maternal 
demographics 
0.583 12% 20% 29% 38% 
FL centile 0.598 28% 36% 50% 52% 
UtA Dopplers 0.761 40% 56% 72% 80% 
Mat demographics + 
FL+ UtA PI 




This screening study evaluated the role of mid pregnancy maternal demographics, fetal biometry 
and UtA Doppler indices, alone or in combination, in prediction of stillbirth in a large population of 
low-risk women attending for routine care at 19-24 weeks of gestation. The findings of the study 
demonstrate that the second trimester assessment does not achieve a high performance in 
detecting term stillbirths and this is consistent with the current available literature (9-16). On the 
other hand, the performance improved to a sensitivity of 35% for a 10% FPR when examining the 
rate of preterm stillbirths. Preterm stillbirths show a strong association with severe intrauterine 
growth restriction (IUGR) explaining why the UtA Doppler indices are the best single predictor (9). 
Moreover, this study shows of the fetal biometry parameters, only the FL centile was an 
independent predictor of IUD in our population of low risk woman. The performance of the 
screening for detection of stillbirth was only marginally improved by the addition of FL to the UtA 
Doppler assessment as showed by ROC curves (Figure 1 and 2). In contrast, second trimester 
assessment performed better than the use of maternal demographic characteristics and risk factors 
as is conventional in clinical practice currently. These discordant findings for gestation of stillbirth 
could be explained either because term stillbirth has a different aetiology or because the interval 
between the assessment and the time of the stillbirth affects the performance of the screening. The 
major strengths of our study include the large number of pregnancies attending for routine 
assessment at 19-24 weeks of gestation, adjusting for possible confounding variables and 
ascertainment of the outcome data. The retrospective design is a limitation and the data could be 
biased by selective assessment of a high risk population based on the availability of UtA Doppler 
indices results to the obstetricians. 
Several biophysical and biochemical tests performed during the first two trimesters of pregnancy 
have been proposed to predict stillbirth (5,9,11) but to date, there is still no clinically useful first or 
 85 
second-trimester test to predict IUD as a sole category in unselected pregnant women. Studies over 
the past two decades have confirmed UtA Doppler as potentially useful in predicting pregnancies at 
high risk of developing complications related to utero-placental insufficiency (9,11,16). Smith et al. 
(9) showed that UtA Doppler at 22-24 weeks’ gestation in a population of low risk unselected 
women is associated with increased risk of all causes of stillbirth up to 32 weeks (sensitivity 58% for 
a FPR of 5%); conversely the prediction at later gestational age was poor with a sensitivity of 7% at 
the same FPR. However, fetal biometry was not included in the analysis and the results of our study 
interestingly show an independent contribution of FL measurement in prediction of stillbirth. In high 
risk women, the use of UtA Doppler indices showed a better performance in predicting stillbirth at 
term (6). The explanation of this difference can be identified in the increased prevalence of stillbirth 
in the high risk population and the influence of intervention bias as abnormal results were revealed 
to clinicians who may have modified the management of the pregnancy (6). 
A recent systematic review and meta-analysis (11) showed that serum levels of pregnancy-
associated plasma protein A (PAPP-A) in the first trimester and UtA PI in the second trimester have 
a high predictive accuracy for stillbirth related to placental dysfunction and pointed out the impact 
that the introduction of such tests could have in reducing the risk of placental dysfunction-related 
stillbirth. Evidence suggests that the detection of a FL below the expected value (< 5th centile) at 
mid-trimester ultrasound examination is a feature of IUGR (17- 19). Weisz et al. (19) showed in a 
large cohort that 20% of cases of isolated short femur in the second trimester were associated with 
subsequently diagnosed IUGR and lower levels of PAPP- A. However, this study did not incorporate 
Doppler analysis. The aetiology of femur shortening in IUGR fetuses is unclear. A study of body 
proportionality of small for gestational age fetuses found that in most cases of small for gestational 
age due to abnormal placentation, the reduced FL was concordant with the small abdominal 
circumference (20). Another study (21) speculated that abnormal placentation altered the level of 
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fibroblast growth factor receptor-2, resulting in growth restriction of the fetal long bones and this 
can account for the finding of isolated short femur in pregnancies with impaired placental function. 
The well-accepted hypothesis that stillbirth is related to multiple aetiologies and not to a single 
disorder makes it unlikely that any single test will be able to predict all-cause stillbirth. The most 
avoidable cause of stillbirth is certainly the one related to an impaired placental function defined as 
IUGR rather than the one based on birth weight-criteria. The results of our study show that a high 
resistance pattern of flow in the UtA in the second trimester is associated with an increased risk of 
stillbirth and that this association is strongest for stillbirths due to placental dysfunction. While 
consistent with other studies, the current comprehensive evaluation of mid pregnancy maternal 
demographics, fetal biometry and UtA Doppler provides evidence that other factors have a relative 
importance for prediction of placental stillbirths such as the finding of shortening of FL. The clinical 
custom of using fetal size as an indicator of adverse outcome makes it difficult to identify placental 
insufficiency near term in a fetus of normal weight. Indeed placental insufficiency can result from 
an abnormal placental development – leading to the early onset fetal growth restriction. 
Alternatively, placental dysfunction may occur because a normally formed placenta is unable to 
cope with the higher fetal metabolic demands as may occur at term with a normal or increased fetal 
size (22). This could explain why the second trimester screening using UtA Doppler indices does not 
achieve a performance good enough in identifying this subset of patients as “high-risk” of term 
stillbirth and suggest that a third trimester assessment might be required. In this scenario it 
becomes a priority to recognize criteria directly related to placental function rather than fetal weight 
population definitions in order to reduce the rate of “unexplained” stillbirth by correctly classifying 
the placental stillbirths. This information may be useful to improve pregnancy outcome by increased 
surveillance and timely intervention. Future studies will be needed to investigate the potential 
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benefit of scheduling further scans and Doppler evaluation for the selected “high risk” pregnancies 






























Fig.1 : Receiver operating characteristic (ROC) curves for screening by 
maternal demographics (smooth black line), Fl centile (round dot 
line), UtA Doppler PI (dash line) and maternal factors, FL centile and 
UtA Doppler PI (square dot line) in the prediction of all stillbirths (left) 


































Fig.2 : Receiver operating characteristic (ROC) curves for screening by maternal 
demographics (smooth black line), Fl centile (round dot line), UtA Doppler PI 
(dash line) and maternal factors, FL centile and UtA Doppler PI (square dot line) 
in the prediction of preterm (< 37 weeks’ gestation) (left) and very preterm (< 
32 weeks’ gestation) stillbirths (right). 
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CHAPTER 9 MANAGEMENT OF FGR 
 
The main strategies in the management of FGR fetuses is the evaluation of fetal wellbeing and 
vitality and the subsequent decision regarding when delivery should take place (1). 
Several studies in the las years focused their attention to identify the correct management of these 
fetuses. “The Growth Restriction Intervention Trial (GRIT)” randomly classified women with FGR 
fetuses  between 24 and 36 weeks of gestation in two different groups: immediate delivery and 
expectant management. Of these patients, 40% had zero or reversed diastolic flow on the 
umbilical artery Doppler. The immediate delivery group had fewer stillbirths (2 versus 9 in the 
expectant group); however, it had more neonatal and infant deaths (27 versus 18), particularly in 
patients with gestations <31 weeks (2). The 13-year follow-up of children showed no differences 
between groups in terms of cognition, language skills, motor skills, or behavioral development (3). 
These data suggest that expectant management of very premature restricted fetuses, when there 
are questions about the time of delivery, will result in some fetal deaths, but immediate delivery 
results in a similar number of neonatal deaths. Neither of the two methods produced a better 
neurological outcome. 
In the “TRUFFLE: A trial of umbilical and fetal randomized flow in Europe” study, 
neurodevelopmental outcome  was assessed at 2 years after delivery for cases of fetuses with early 
onset FGR born before 32 weeks. Fetuses were divided into three groups on the basis of the delivery 
time and different fetal wellbeing assessment strategies: group 1 reducing the short-term variation 
in computerized cardiotocography;  Group 2 early changes in DV (95th percentile), and Group 3 late 
changes in the DV (zero wave). Most deliveries were recommended for reasons other than changes 
that recommended delivery in each group. The groups that were based on the DV Doppler used 
cardiotocography as a safety criterion, whereas in the cardiotocography group, a safety criterion 
was not applied to the DV Doppler. The hypothesis was that a slight worsening in the prognosis of 
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the cardiotocography group could be explained by the lack of information from the DV Doppler. 
Therefore, the authors concluded that to optimize the decision regarding the time of delivery in 
cases of early onset FGR, fetuses should be monitored longitudinally using a DV Doppler and 
computerized cardiotocography (4). 
The objective of a clinical protocol for the management of FGR is to combine the existing evidence 
on various assessment of fetal wellbeing (cardiotocography, biophysical profile, and Doppler) to 
achieve better growth and lung maturity and minimize the risk of morbidity as well as fetal and 
neonatal mortality. This decision is often based on the gestational age, etiology of growth 
restriction, extent to which the fetus is compromised, and experience and technological resources 
available for the evaluation of the fetus and for neonatal treatment. The delivery should be 
preferably performed in a tertiary hospital.  
 
CHAPTER 9.1 Management of SGA fetuses 
Fetal wellbeing with doppler velocimetry and biophysical profile and growth should be performed 
every 2 weeks. If the patient does not go into labor spontaneously, labor may be induced at 40 
weeks. It is recommended to avoid the use of prostaglandins in the induction of labor because of 
the risk of hyperstimulation in fetuses that may have some degree of placental injury (5).  
 
CHAPTER 9.2 Management of FGR fetuses with normal Doppler) 
Fetal wellbeing with doppler velocimetry and biophysical profile and growth should be performed 
every week for fetuses in which the estimated fetal weight is below the third percentile without 
Doppler anomalies. Birth may be induced around 38 weeks, but the use of prostaglandins should be 




CHAPTER 9.3 Management of FGR with moderate placental insufficiency (with 
Doppler changes, Stage I) 
In case of the presence of umbilical artery PI > the 95th percentile with positive EDF, median cerebral 
artery PI < the fifth percentile, or CPR < the fifth percentile on the Doppler, the evaluation of fetal 
wellbeing is recommended every week.  
The induction of birth at 37 weeks is acceptable, but the use of prostaglandins should be avoided. 
Furthermore, there is also the risk of intrapartum fetal distress (6). If it is not possible rigorous fetal 
monitoring or there is suspected or abnormal test, CTG or biophysical profile, delivery should be 
considered between 34 and 37 weeks of gestation to avoid adverse perinatal outcome. 
 
CHAPTER 9.4 Management of FGR with severe placental insufficiency (Doppler of 
the umbilical artery with zero diastolic flow, Stage II) 
 
FGR fetuses with zero diastolic flow on the umbilical artery Doppler or reversed diastolic flow, needs 
to be monitored every 2 or 3 days [4]. Delivery at 34 weeks, usually by the elective cesarean section, 
is recommended, because the risk of fetal distress in labor induction exceeds 50% (5). 
 
CHAPTER 9.5 Management of FGR with advanced fetal deterioration (umbilical 
artery Doppler with reversed diastolic flow or DV with pi > 95th percentile, Stage III) 
 
In case of the presence of reversed diastolic flow on the umbilical artery Doppler or PI > the 95th 
percentile on the DV Doppler, there is a high risk of fetal death and impaired neurological 
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development. Hospitalization and daily fetal monitoring (Doppler and cardiotocography) are 
recommended. Delivery is recommended at 30 weeks (5).  
 
CHAPTER 9.6 Management of FGR with high probability of fetal acidosis and high 
risk of fetal death (Doppler of DV with reversed wave, computerized 
cardiotocography <3 ms, or decreased fetal heart rate, Stage IV) 
 
In case of a DV Doppler with a reversed wave, short-term variation in computerized 
cardiotocography <3 ms or decreased fetal heart rate, delivery by the elective cesarean section is 
recommended, depending on the availability of NICUs. 
Parents should receive counseling according to the data of viability without sequelae according to 
the gestational age and their opinion should be taken into consideration in the delivery decision (5). 
Fetal monitoring should begin between 24 and 26 weeks and should preferably be performed by 
combining the available tests (Doppler, fetal biophysical profile, and cardiotocography) to improve 
the prediction of acidosis and fetal death (7). 
The prenatal use of corticosteroids should occur between 24 and 34 weeks, preferably in the week 
preceding the scheduled date for delivery, to accelerate fetal lung development and to reduce the 
risk of intracranial hemorrhage (8). However, shortly after the use of corticosteroids, the Doppler 
indices may present an improvement that is only transitory. For deliveries before 32 weeks, the use 
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CHAPTER 10 PERINATAL COMPLICATIONS AND LONG-TERM 
NEURODEVELOPMENTAL OUTCOME OF INFANTS WITH FETAL 
GROWTH RESTRICTION 
 
Neonates who are born with FGR have different types of short-term and long-term issues making 
them vulnerable to mortality and morbidity, both immediately and also on long- term follow-up. 
For these reasons these neonates needs to be followed up for delayed onset of neurological 
problem so that early intervention can be started on both neurological and physical aspect and lead 
to better outcome.  
 
CHAPTER 10.1 Short-term complications of FGR neonates 
 
These infants could face many problems soon after birth. Severely affected FGR infants, subjected 
to oxygen and nutrients deprivation, may have difficult cardiopulmonary transition with perinatal 
asphyxia, meconium aspiration or persistent pulmonary hypertension (PPHN). Immediate neonatal 
com- plications include hypothermia, hypoglycaemia, hyperglycaemia, hypocalcaemia, 
polycythaemia, jaundice, feeding difficulties, feed intolerance, necrotizing enterocolitis, late onset 
sepsis and pulmonary haemorrhage (1).  
Perinatal mortality is high in these neonates as compared with their AGA counterpart. This is seen 
because of adverse effect prolonged intrauterine hypoxia, birth asphyxia, sudden sentinel obstetrics 
events, including abruption, cord prolapse and associated congenital anomalies seen in this group 
(2,3). 
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Prevention of perinatal asphyxia includes regular antenatal and intrapartum monitoring, regular 
fetal growth monitoring by ultrasound, conducting delivery at appropriate time and early 
identification of complications with prompt referral and efficient neonatal resuscitation. It has been 
showed that he rate of score Apgar<7 at 5min of life was significantly higher in SGA infants when 
compared with AGA (RR = 2.0; 95% CI 1⁄4 1.9– 2.1) (4). 
Katz et al. in a pooled analysis of 20 cohorts from developing population showed that in comparison 
with term AGA infants, the RR for neonatal mortality was 1.83 (95% CI 1.34–2.50) and post- neonatal 
mortality RR was 1.90 (1.32–2.73) for SGA infants. The risk of neonatal mortality was maximum in 
babies who were both preterm and SGA in comparison to babies who were either SGA or preterm 
alone (15.42; 9.11–26.12) (5). 
Hypoglycaemia is the results of decreased glycogen stores, gluconeogenesis, increased sensitivity 
to insulin, decreased adipose tissue and decreased ability to oxidize free fatty acids and triglycerides 
effectively. Hypoglycaemia could also be due to asphyxia, polycythaemia or hypothermia. For these 
reasons, FGR neonates need careful sugar monitoring during the first days of life with early feeding 
after birth with monitoring of sign and symptoms of hypoglycaemia (1,6). 
Hyperglycaemia is also seen sometimes in these FGR infants secondary to low insulin secretion rate, 
excessive exogenous glucose delivery and increased catecholamine and glucagon effects (6). 
Management includes regular monitoring of sugar level and avoiding too much glucose infusion (7). 
Another common short-term complication is hypothermia. Hypothermia could be due to multiple 
causes, which includes relatively large body surface area, decreased body and subcutaneous tissue 
fat, impaired thermoregulation and catecholamine depletion. In addition, simultaneous occurrence 
of either hypoxia or hypoglycaemia can interfere with heat production (8).  
Polycythaemia is defined as venous haematocrit more than 65%. Polycythaemia and 
leukoneutropenia in FGR infants is due to increased synthesis of erythropoietin secondary to chronic 
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intrauterine hypoxia (9,10). These FGR infants should be monitored for haematocrit at 2, 12 and 24 
h after birth. If the infant is symptomatic, polycythaemia can be managed with partial volume 
exchange and fluid supplementation (11,12).  
Chronic hypoxia in FGR infants could also cause PPHN, who may lead to remodelling of pulmonary 
vasculature, with extension of muscularis layer of blood vessels to intra-acinar arteries. This PPHN 
could also be secondary to hypocalcaemia, polycythaemias, hypoglycaemia or infections, seen in 
them. Management of PPHN includes avoiding hypoxia and hyperoxia, normalization of metabolic 
milieu, cardiovascular support, pulmonary vasodilator and mechanical ventilation (13,14). 
Meconium aspiration syndrome (MAS) is seen in these FGR infants because of chronic hypoxia 
leading to meconium-stained liquor (MSL) and aspiration. It can occur at different stages, mild to 
severe MAS requiring ventilation. Management includes intrapartum fetal monitoring and early 
detection of MSL. Treatment involves adequate ventilation with prevention of hypoxia, adequate 
lung recruitment and management of PPHN (15) 
Feed intolerance and necrotizing enterocolitis (NEC) is seen frequently in these FGR neonates (16). 
NEC is caused by decreased intestinal perfusion due to shunting of blood in response to hypoxia to 
vital organs, including heart, brain and adrenals, focal ischemia and hypoperistalsis (17). The 
incidence of NEC is increased further in FGR infants with absent or reversed end diastolic flow in the 
umbilical artery Doppler’s (18). Management includes avoiding rapid increase in feeds, cautious 
enteral feeding, minimal enteral nutrition and preferable only breast milk (19). 
Neurobehavioural abnormalities are also seen in this group of infants. In a study conducted by 
Padidela et al. who evaluated the neurobehaviour of term appropriate for gestational and SGA 
babies during the first two weeks of life using Brazelton neurobehavioural assessment scale 
reported that the behaviour performance of SGA babies on day 3, compared with AGA babies, was 
lower in all the clusters except orientation where they performed much better. The percentage 
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improvement of scores in SGA babies was higher than in AGA babies and by day 14, SGA babies 
were scoring higher than AGA babies in orientation, autonomic stability and regulation of state (20). 
 
CHAPTER 10.2 Long-term neurodevelopmental outcome 
 
FGR infants have high probability of having subtle cognitive and neurodevelopmental abnormalities 
when compared with their AGA counterparts of same gestational age. The neurodevelopmental 
outcome of FGR infants depends upon the type of FGR, perinatal events like maternal hypertension 
(21), Doppler abnormalities (22,23), and perinatal asphyxia and also on the postnatal course like 
hypoglycaemia, neonatal sepsis, meningitis, hypoxic-ischemic encephalopathy and NEC (24).  
The most common neurodevelopmental anomalies seen in FGR fetuses are:  
• Lower scores on cognitive testing 
• School difficulties or requirement of special education 
• Gross motor and minor neurologic dysfunction 
• Behavioural problems (attention deficit hyperactivity syndrome) 
• Growth failure 
• Reduced strength and work capacity 
• Cerebral Palsy 
• Low social competence 
• Poor academic performance  
• Lower Intelligence  
• Poor perceptual performance 
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Martorell et al. in their systematic review of 12 studies reported that FGR infants, male and female, 
performed poorly on tests of strength and hence could apply approximately 2–3 kg less force to a 
hand grip dynamometer and had lower work capacity in comparison to AGA group (25). 
In a study from India, cohort of 161 low birth weights (weight <2000 g at birth) were followed-up 
from birth till 18 years of age. The authors reported that among the enrolled infants SGA subjects 
had the lowest IQs (percentile 35.5) although within the normal range for age. SGA infants were 
also poor in visuo-motor perception, motor incompetence, reading and mathematics learning [26]. 
The adverse effects of FGR on brain structure have a variety of consequences for function. FGR 
infants born preterm and assessed at term equivalent age demonstrate functional deficits in 
neurobehavioral score for attention and responsivity, compared to appropriately grown preterm 
infants, with cerebral cortex grey matter volume correlated to attention–interaction score (27). At 
7 months of age, FGR infants perform more poorly on a visual recognition memory task than age-
matched appropriately grown infants (28). Preterm FGR infants followed-up at 1, 2 and 3 years of 
age showed deficits in developmental and behavioural outcomes, compared to preterm age-
matched appropriately grown infants, but it is interesting to note that preterm FGR infants were 
not different from birthweight matched controls (that is, infants who were born at an earlier 
gestation but were not growth restricted) (29) Leitner et al. performed a longitudinal study from 
birth to 9–10 years in children born with late-onset FGR with evidence of brain sparing. This study 
showed that FGR children have a complex set of neurodevelopmental deficits compared to age-
matched appropriately grown children (30). While suboptimal cognitive performance (IQ<85) was 
apparent in 15% of FGR children, they were also more likely to have specific learning disabilities 
such as reduced memory performance and visuomotor functions, attention and behavioural deficits 
(30). Where brain sparing (CPR <5th centile) was apparent, IQ at 5 years of age was 9 points lower 
compared to children with a normal CPR (31). Multiple follow-up studies of FGR infants into school-
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age childhood find deficits in gross and fine motors kills, cognition, memory and academic ability, 
as well as neuropsychological dysfunctions encompassing poor attention, hyperactivity and altered 
mood (33-36). 
It is apparent from the literature that determining the neurodevelopmental consequences of FGR is 
complicated by the severity of FGR, early or late onset, and the gestational age at delivery (37). 
Early-onset severe FGR is considered high risk for deficits in outcome, and indeed at school age, 
severe FGR children perform worse on assessment tasks for cognition, motor function, behaviour 
and educational achievements than children who had mild to moderate FGR, or preterm 
appropriately grown children (38) Preterm birthis likely to be an exacerbating factor when 
describing the neurological outcomes associated with FGR, and Yanney & Marlow [39] suggest that 
preterm birth over-rides the effects of FGR per se. 
It has also been shown that serious neurodevelopmental consequences are more prevalent in FGR 
infants who demonstrate perinatal acidosis (40), suggesting that a secondary acute compromise has 
profound additive adverse effects in fetuses that have experienced chronic antenatal hypoxia. 
A number of studies have analysed results based on the child’s gender, where sex differences may 
influence neurodevelopmental outcomes for FGR infants. Parkinson and colleagues reported that 
poor school achievement and behavioural problems were more frequently observed in boys with 
early-onset growth restriction (41). This is supported by another study showing that FGR boys born 
very preterm (24–29weeks) were at the greatest risk of cognitive impairment examined at school 
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CHAPTER 11 STUDY 4:  
Motor and neurodevelopmental outcome of infants with 






FGR, is a major public health problem, and it is the second leading cause of perinatal mortality and 
morbidity worldwide, only second to preterm delivery (1,2). FGR is estimated to occur in 5% to 7% 
of all pregnancies.  
It is important to separate between infants who are small for gestational age (SGA) and those who 
have experienced true FGR, which is generally due to placental insufficiency and is associated with 
an abnormal Doppler velocimetry on fetal and maternal ultrasound (3).  
Approximately 5% to 10% of all pregnancies complicated by FGR result in stillbirth or neonatal death 
(4), and impaired fetal growth is responsible for at least 25% of all stillbirths (5). Placentally 
restricted fetuses are chronically hypoxemic and hypoglycemic and have increased blood lactate 
concentrations (4). Most infants with FGR show an increased postnatal growth velocity with catch-
up growth by 2 to 3 years (6). However, because infants with FGR have feeding problems and 
decreased nutritional stores, approximately 10% remain susceptible to sustained growth delay (7). 
It has been established that the effects of been born IUGR continue also beyond the neonatal period 
and the literature had widely investigated the long-term consequences of being born FGR on health 
and physical well-being.  
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Although several follow-up studies showed neurodevelopmental delay in children with FGR, these 
studies have not been systematically reviewed and the information, such as the definition of FGR, 
are often discordant between the studies and has not been adequately assessed.  
The aim of this study was to prospectively evaluate the neurodevelopmental outcomes, particularly 
the neuro-motor assessment, in a cohort of FGR newborn at 6 and 12 months corrected age using 
the Bayley Scales of Infant and Toddler Development (3rd edition) (Bayley-III edition) and to 
compare them to a cohort of SGA infants and appropriate-for-the-gestational age (AGA) infants.   
 
METHODS 
Study design and participants 
We performed a single-centre longitudinal prospective case-control study between November 2016 
and October 2019. The study protocol was approved by the regional ethics committee. Patients 
included in the study signed a general consent form for the use of their data for scientific purposes. 
Inclusion criteria were: singleton pregnancy morphologically normal, attending their routine 
scheduled ultrasound examination between 19 and 24 weeks of gestation and between 29 and 32 
weeks of gestation, maternal age >18 years old, newborn infants with intrauterine diagnosis of FGR, 
newborn infants SGA and newborn infants AGA. Pregnancies complicated by fetal abnormality, 
maternal medical disorders, aneuploidy or infection were excluded from the analysis. 
In the first pregnancy-trimester, the measure of crown–rump length (CRL) was used for dating 
pregnancies according to the NICE (National Institute for Health and Clinical Excellence) guidelines 
(8). 
At the time of 11–14 weeks of pregnancy, PAPP-A levels were measured as first-trimester combined 
screening test for Down syndrome. Both at the time of routine ultrasonography at 11–14 weeks and 
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of routine anomaly abdominal ultrasonography at 19–23 weeks of pregnancy, uterine artery (UtA) 
Doppler indices were evaluated; pulsatility index (PI) of the left and the right UtA was averaged to 
obtain mean PI, which was plotted against a published reference range (9). During the third 
pregnancy trimester, at 29–32 weeks, an ultrasonographic scan was done in all the patients to 
evaluate fetus growth and fetal doppler assessment.  
At the first study visit, baseline maternal characteristics, including age, ethnic origin, and body mass 
index (BMI), parity and smoking were recorded. The maternal and neonatal outcomes of each 
pregnancy were collected. Delivery or follow-up scans were arranged as appropriate for any 
suboptimal assessments. 
Gestational complications were defined with standardized criteria: pregnancy induced hypertension 
(PIH), detecting after 20 gestation weeks a blood pressure persistently over 140/90 mmHg in a 
woman with previously normal pressure values; preeclampsia, in case of gestational hypertension 
and concomitant proteinuria (>300 mg/24 h); preterm birth, indicating a delivery before the 
completion of 37 gestation weeks; SGA, in case of an infant with birth weight less than the 10th 
centile for gestational age with normal fetal and maternal Doppler assessment; and IUGR, according 
to consensus-based definitions for early and late IUGR, Delphi procedure (10).  
 
Neurodevelopmental assessment 
Children and their families were invited to take part in a follow-up assessment with Bayley Scales of 
Infant and Toddler Development (3rd edition)(Bayley-III) at 6 months and at 12 months corrected 
age.  
The Bayley-III generates scores for 3 composite indices (Cognitive, Language, Motor) and 5 subtests 
(Cognitive, Expressive Communication, Receptive Communication, Fine Motor, Gross Motor). 
motion and balance) subtests. The Bayley Scales have index mean scores of 100 (SD ± 15). In the 
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present study, an index composite score of < 70 (>2 SD below the mean) is defined to indicate severe 
impairment, while an index composite score of 70–84 (>1 SD below the mean) is defined to indicate 
mild impairment. Index composite scores ≥ 85 are defined here to indicate normal development. 
The Italian validated translation of the administration manual was used (11). 
 
Statistical analysis 
The Kolmogorov–Smirnov test of normality was used for assessing the distribution of data, which 
were expressed as mean (SD), or median and interquartile range as appropriate. Categorical 
variables were described as number (%). The correlations between continuous variables were 
evaluated by Pearson coefficient or by Spearman rho and those between categorical variables were 
evaluated by Pearson x2 test. Continuous variables were compared by Mann–Whitney and 
independent t-tests. 
Mean UtA Doppler PI, estimated fetal weight (EFW) centiles, and z-scores were calculated by using 
appropriate previously described reference ranges (9). Mean UtA Doppler PI was corrected for 
gestational age; multiple of medians were calculated by using the reference ranges extracted from 
the published centiles (9). P < 0.05 was considered statistically significant. Appropriate statistical 
software (SPSS 20.0; SPSS Inc, Chicago, IL) was employed for the statistical data analysis. 
 
RESULTS 
Demographic, pregnancy characteristics and postnatal outcomes of the three groups of patients are 
presented in Tables 1, Table 2 and Table 3.  
There was no statistically significant difference in the baseline data within the three study groups. 
Overall, 81 newborn had complete follow-up, as required for being eligible for the study analysis; 
within this population, 27 (33,3%) were FGR, 27 (33,3%) were SGA, and 27 (33,3%) were AGA. 
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Comparing IUGR group to AGA group, pregnant women presented significantly lower first-trimester 
PAPP-A level, and significantly higher first-trimester and mid-pregnancy mean UtA-PIs. Moreover, 
the IUGR group had a significantly lower gestational age (GA) at the time of delivery and a 
significantly higher admission rate to neonatal intensive care unit (NICU) compared to the AGA 
group (Table 1). 
Comparing IUGR group to SGA group, pregnant women presented significantly higher first-trimester 
and mid-pregnancy mean UtA-PIs, significantly lower GA and birth weight (BW) at the time of 
delivery and a significantly higher admission rate to NICU compared to the AGA group (Table 2).  
A statistically significant difference was not observed in the first trimester levels of PAPP-A and first 
trimester and mid-pregnancy mean UtA Doppler PI between SGA and AGA group. A statistically 
significant lower GA and BW was observed, however no difference has been observed in the NICU 
admission rate (Table 3).  
The composite indices (Cognitive, Language, Motor) were significantly lower in FGR group compared 
to AGA group both at 6 and 12 months evaluation (Table 4).  The composite indices (Cognitive, 
Language, Motor) were significantly lower in FGR group compared to SGA group at 6 month 
evaluation. However, at 12 months evaluation only the Motor composite indices was significantly 
lower in IUGR group, Table 5.  
Comparing the AGA and SGA groups, no statistically significant difference was found at 6 month 
evaluation for all the composite indices (Cognitive, Language, Motor). However, at 12 months 










































Data are shown as median (interquartile range), mean (standard deviation) or number (%). 
 
Body Mass Index: BMI; pregnancy-associated plasma protein A: PAPP-A; beta human chorionic 
gonadotropin: BhCG; estimated fetal weight: EWF; birth weight: BW; neonatal intensive care unit: 
NICU; fetal growth restriction: FGR; appropriate for gestational age: AGA; Uterine artery: UtA; 





(n = 27 ) 
AGA 
(n = 27 ) 
P value 
Demographics    
Maternal age, (years, 
median, IQR) 
29,6 (27,5-32,5) 31,7 (29,0-35,0) 0,074 
Nulliparous (n, %) 22 (81,5) 22 (81,5) 1,000 
BMI (kg/m2, mediana, IQR) 22,9 (21,0 – 25,0) 23,2 (21,6-24,5) 0,757 



















4 (14,8) 0,311 
Smoking (n, %) 5 (18,5) 4 (14,8) 0,751 
1st and 2nd trimester 
variables 
   
PAPP-A (MoM, mediana, 
IQR) 
0,81 (0,48-1,11) 1,17 (0,66-1,83) <0,05 
BhCG (MoM, mediana, IQR) 1,04 (0,67-1,46) 1,23 (0,93-1,58) 0,174 
Mean UtA PI 1st trimester 
(median, SD) 
2,01 (±0,50) 1,52 (±0,69) <0,05 
Mean UtA PI 2nd trimester 
(median, SD) 
1,65 (±0,55) 0,98 (±0,24) <0,05 
Scan assessment during the 
3rd trimester of pregnancy 
   
Gestational age 3rd 
trimester scan (median, SD) 
33,4 (±1,3) 32,3 (±2,0) 0,810 
EFW (g, mean, SD) 1495 (±205) 1909 (±351) <0,05 
EFW centile (mean, SD) 5,7 (±3,9) 49,9 (±27,5) <0,05 
Pregnancy and perinatal 
outcome 
   
Gestational age delivery 
(median, IQR) 
36,9 (±1,4) 39,0 (±1,4) <0,05 
BW (mean, SD) 2192 (±322) 3319 (±404) <0,05 
BW centile (mean, SD) 4,4 (±3,3) 49,1 (±25,3) <0,05 
NICU admission (n, %) 10 (37,0) 2 (7,4) <0,05 
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Data are shown as median (interquartile range), mean (standard deviation) or number (%). 
 
Body Mass Index: BMI; pregnancy-associated plasma protein A: PAPP-A; beta human chorionic 
gonadotropin: BhCG; estimated fetal weight: EWF; birth weight: BW; neonatal intensive care unit: 






(n = 27 ) 
SGA 
(n = 27 ) 
P value 
Demographics    
Maternal age, (years, median, 
IQR) 
29,6 (27,5-32,5) 29,1 (26,5-32,0) 0,658 
Nulliparous (n, %) 22 (81,5) 20 (74,1) 0,513 
BMI (kg/m2, mediana, IQR) 22,9 (21,0 – 25,0) 22,5  (20,0-24,5) 0,596 


















6 (22,2) 0,750 
Smoking (n, %) 5 (18,5) 5 (18,5) 1,000 
1st and 2nd trimester 
variables 
   
PAPP-A (MoM, mediana, IQR) 0,81 (0,48-1,11) 0,87 (0,60-0,98) 0,611 
BhCG (MoM, mediana, IQR) 1,04 (0,67-1,46) 1,05 (0,57-1,37) 0,931 
Mean UtA PI 1st trimester 
(median, SD) 
2,01 (±0,50) 1,49 (±0,49) <0,05 
Mean UtA PI 2nd trimester 
(median, SD) 
1,65 (±0,55) 0,98 (±0,30) <0,05 
Scan assessment during the 
3rd trimester of pregnancy 
   
Gestational age 3rd trimester 
scan (median, SD) 
33,4 (±1,3) 32,9 (±0,97) 0,068 
EFW (g, mean, SD) 1495 (±205) 1626(±203) <0,05 
EFW centile (mean, SD) 5,7 (±3,9) 6,7 (±2,9) 0,321 
Pregnancy and perinatal 
outcome 
   
Gestational age delivery 
(median, IQR) 
36,9 (±1,4) 37,9 (±1,7) <0,05 
BW (mean, SD) 2192 (±322) 2331 (±303) 0,109 
BW centile (mean, SD) 4,4 (±3,3) 4,5 (±2,9) 0,837 
NICU admission (n, %) 10 (37,0) 4 (14,8) 0,062 
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Data are shown as median (interquartile range), mean (standard deviation) or number (%). 
 
Body Mass Index: BMI; pregnancy-associated plasma protein A: PAPP-A; beta human chorionic 
gonadotropin: BhCG; estimated fetal weight: EWF; birth weight: BW; neonatal intensive care unit: 
NICU; appropriate for gestational age: AGA; small for gestational age: SGA; Uterine artery: UtA; 
Pulsatility index: PI 
 
AGA 
(n = 27 ) 
SGA 
(n = 27 ) 
P value 
Demographics    
Maternal age, (years, 
median, IQR) 
31,7 (29,0- 35,0) 29,1 (26,5-32,0) 0,121 
Nulliparous (n, %) 22 (81,5) 20 (74,1) 0,513 
BMI (kg/m2, mediana, IQR) 23,2 (21,6-24,5) 22,5  (20,0-24,5) 0,361 














Previous early miscarriage 
(n, %) 
4 (14,8) 6 (22,2) 0,484 
Smoking (n, %) 4 (14,8) 5 (18,5) 0,715 
1st and 2nd trimester 
variables 
   
PAPP-A (MoM, mediana, 
IQR) 
1,17 (0,66-1,83) 0,87 (0,60-0,98) 0,098 
BhCG (MoM, mediana, 
IQR) 
1,23 (0,93-1,58) 1,05 (0,57-1,37) 0,221 
Mean UtA PI 1st trimester 
(median, SD) 
1,52 (±0,69) 1,49 (±0,49) 0,899 
Mean UtA PI 2nd trimester 
(median, SD) 
0,98 (±0,24) 0,98 (±0,30) 0,994 
Scan assessment during 
the 3rd trimester of 
pregnancy 
   
Gestational age 3rd 
trimester scan (median, 
SD) 
32,3 (±2,0) 32,9 (±0,97) 0,116 
EFW (g, mean, SD) 1909 (±351) 1626(±203) <0,05 
EFW centile (mean, SD) 49,9 (±27,5) 6,7 (±2,9) <0,05 
Pregnancy and perinatal 
outcome 
   
Gestational age delivery 
(median, IQR) 
39,0 (±1,4) 37,9 (±1,7) <0,05 
BW (mean, SD) 3319 (±404) 2331 (±303) <0,05 
BW centile (mean, SD) 49,1 (±25,3) 4,5 (±2,9) <0,05 
NICU admission (n, %) 2 (7,4) 4 (14,8) 0,386 
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Table 4. The Bayley-III generates scores for 3 composite indices (Cognitive, Language, Motor) at 6 






















Data are shown as mean (standard deviation).  
 
























(n = 27 ) 
AGA 
(n = 27 ) 
P value 
Bayley score 6 
months 
   
Cognitive indices 
(mean, SD) 
80,4 (± 6,7) 88,1 (±4,7) <0.05 
Motor indices (mean, 
SD) 
79,6 (±7,2) 86,8 (±5,1) <0,05 
Language indices 
(mean, SD) 
81,2 (±6,6) 87,1 (± 5,2) <0,05 
Bayley score 12 
months 
   
Cognitive indices 
(mean, SD) 
83,4 (± 5,6) 89,6 (± 3,9) <0,05 
Motor indices (mean, 
SD) 
80,7 (± 7,0) 89,0 (± 3,6) <0.05 
Language indices 
(mean, SD) 
83,4 (± 6,4) 88,5 (± 6,7) <0,05 
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Table 5. The Bayley-III generates scores for 3 composite indices (Cognitive, Language, Motor) at 6 


















Data are shown as mean (standard deviation).  
 




























(n = 27 ) 
SGA 
(n = 27 ) 
P value 
Bayley score 6 months    
Cognitive indices (mean, 
SD) 
80,4 (± 6,7) 85,6 (±6,4) <0,05 
Motor indices (mean, SD) 79,6 (±7,2) 84,3 (±5,1) <0,05 
Language indices (mean, 
SD) 
81,2 (±6,6) 85,4 (±5,9) <0,05 
Bayley score 12 months    
Cognitive indices (mean, 
SD) 
83,4 (± 5,6) 85,4 (±5,8) 0,206 
Motor indices (mean, SD) 80,7 (± 7,0) 85,6 (±5,1) <0,05 
Language indices (mean, 
SD) 
83,4 (± 6,4) 85,9 (±5,1) 0,124 
 117 
Table 6. The Bayley-III generates scores for 3 composite indices (Cognitive, Language, Motor) at 6 




















Data are shown as mean (standard deviation).  
 
















(n = 27 ) 
SGA 
(n = 27 ) 
P value 
Bayley score 6 months    
Cognitive indices 
(mean, SD) 
88,1 (±4,7) 85,6 (±6,4) 0,106 
Motor indices (mean, 
SD) 
86,8 (±5,1) 84,3 (±5,1) 0,075 
Language indices 
(mean, SD) 
87,1 (± 5,2) 85,4 (±5,9) 0,265 
Bayley score 12 months    
Cognitive indices 
(mean, SD) 
89,6 (± 3,9) 85,4 (±5,8) 0,089 
Motor indices (mean, 
SD) 
89,0 (± 3,6) 85,6 (±5,1) <0,05 
Language indices 
(mean, SD) 




This study demonstrate that the mean score for the Cognitive, Language and Motor indices were 
significantly lower in FGR group compared both to AGA group and SGA group at 6 months 
evaluation. However, at 12 months examination, while all the indices remained significantly lower 
in IUGR group compared to AGA group, in the comparison with the SGA group only the motor score 
remained significantly lower in the FGR group. Moreover, comparing the AGA and SGA groups, no 
statistically significant difference was found at 6 month evaluation for all the composite indices 
(Cognitive, Language, Motor). However, at 12 months evaluation the Motor composite indices was 
significantly lower in SGA group.  
 
Interpretation 
The findings of our study confirm previous observations that FGR infants are at increased risk for 
adverse neurodevelopmental outcome compared to AGA and SGA infants (12,13).  
According to the existing literature four studies examined neurodevelopmental outcome in children 
with FGR between 6 months and 1 year of age. Two of these study defined IUGR only according to 
the low birth weight or fetal abdominal circumference below the 5Th centile, without references to 
fetal and maternal doppler assessment (14,15). The first study performed by Fernandez-Carrocera 
et al. (14), showed that infants with FGR had higher prevalence of neuromotor and neurologic 
abnormalities than controls at 1 year, although most of the abnormalities were mild. FGR was the 
best predictor marker of neurological impairment at 1 year. Moreover, they also showed that 
infants with FGR scored significantly lower than controls on the Bayley Scales of Infant 
Development, version II (Bayley-II), although both groups scored within 1 SD of the mean (14). In 
the second study, Roth et al (15), compared at 1 year of age neurological outcome between FGR 
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and SGA infants. They defined FGR as a change in fetal abdominal circumference >1.5 SD between 
the first and last scan, whereas SGA was indicated when fetal abdominal circumference changed 
<1.5 SD, and found no significant differences in neurodevelopment between these groups. 
However, approximately 1/3 of FGR and SGA infants had some neurological damage.  
The other two studies conducted with children between 6 months and 1 year of age, who had 
prenatal diagnosis of FGR, included abnormal Doppler parameters in their definition (16,17). In the 
first study, preterm infants with asymmetric FGR had significantly lower neurobehavioral scores on 
the habituation, motor system, social-interactive, and attention subscales of the Neonatal 
Behavioral Assessment Scale at 40 weeks when compared with both controls and infants with 
symmetric FGR. Asymmetric fetal growth restriction, mainly due to the “brain-sparing” effect, 
occurs late in pregnancy, and infants show weight reduction but a less marked length reduction. In 
the second study, Padilla et al. (17) compared preterm children with and without FGR using the 
Hammersmith Infant Neurologic Examination and the Bayley-II at 1 year of age, and found no 
significant differences between the groups in neurodevelopmental performance. Thus, three of the 
four studies assessing neurodevelopment between 6 months and 1 year indicate that these children 
are at higher risk for neurodevelopmental delay. 
Accumulating evidence suggests that cerebral redistribution may be associated with increased risk 
of adverse neurodevelopmental outcomes (18-22). A recent systematic review suggest that cerebral 
redistribution in SGA fetuses may not be an entirely protective phenomenon (23). Cerebral 
redistribution in term SGA fetuses was found to be associated with increased risk of problems in 
neonatal motor and state organization, and lower communication and problem-solving scores at 2 
years of age. Cerebral redistribution in preterm SGA fetuses was also found to be associated with 
increased risk of abnormal psychomotor development at 1 year of age. Few studies reported long-
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term outcomes, and maximum follow up was 2 years (23). Longitudinal data are limited; therefore, 
the prognostic clinical significance of early neurological findings is uncertain.  
Doppler studies investigating cerebral redistribution in fetal growth restriction suggest that an 
increase in frontal lobe perfusion occurs first, detected by changes in the anterior cerebral artery. 
This is followed by changes in the middle cerebral artery (MCA), which supplies the basal ganglia 
and influences motor function. As MCA changes are indicative of an advanced stage of brain sparing, 
it is possible that impact on cognitive function through abnormal frontal lobe perfusion has already 
occurred by the time that MCA changes are detected (24,25).  
Although cerebral redistribution may offer neuroprotection in some, this may not completely 
mitigate the effects of hypoxia and it is unknown at what point following cerebral redistribution 
there is an increased risk of adverse neurodevelopmental sequelae.  
 
Strengths and limitations 
The first limitation is the small sample size. The small number of newborn in each group did not 
allow further subanalysis to be performed, particularly the analysis according the GA at birth. For 
this reason is not possible to exclude the impact of being born preterm on the neurodevelopmental 
outcomes. The second major limitation is the short follow-up period. A longer follow-up could have 
gave us a better neurological assessment, in particular underlining the differences between the 
various domains between the three study groups.  However, these preliminary findings may pave 
the way for future studies with a larger sample size and a longer follow-up. The main strength of 
this study is that we classified our study population according to distinct signs of placental 
dysfunction including prenatal fetal and maternal Doppler parameters and analyzed the short-term 
outcome of FGR infants compared with children being SGA without such signs of placental 
insufficiency. This design seems to be advantageous compared with the majority of pediatric studies 
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on short and long-term outcome using a mixed population of newborns just being small or light at 
birth. The latter might lead to a bias by underestimating the real impact of intrauterine growth 
restriction on neurological outcome.  
 
CONCLUSION 
In conclusion, the current study shows that FGR newborn had a significantly lower mean score on 
each domains (Cognitive, Language and Motor) at 6 months compared to SGA and AGA infants. 
However, at 12 months examination, while all the indices remained significantly lower in FGR group 
compared to AGA group, in the comparison with the SGA group only the motor score remained 
significantly lower in the FGR group, probably due to the fetal cerebral distribution that may affect 
mainly the motor centers.  
Further follow-up studies would be helpful to expand existing knowledge of the effects of IUGR on 
neurodevelopment in early childhood, but it is essential to standardize definitions, study designs, 
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CHAPTER 12. CONCLUSION 
 
FGR remains a leading contributor to perinatal mortality and morbidity and metabolic syndrome in 
later life. Significant advances have been made in the understanding of the complex etiology and 
pathophysiology of FGR. This knowledge will certainly aid the clinician to optimize antepartum 
monitoring and time delivery of FGR infants. 
It is well known that the etiology of FGR can be categorized into maternal, fetal and placental 
factors. In this three year project one of our research line was to evaluate the impact of some 
maternal condition, such as adenomyosis and endometriosis, on the incidence of FGR.  
The first study, published in 2018, had the aim of evaluate maternal and fetal outcomes, in particular 
the incidence of FGR, in a cohort of women with endometriosis with or without the concomitant 
presence of diffuse or focal adenomyosis. This was a retrospective study, with a relatively small 
number of patients recruited, however the results were quite interesting. The results showed that 
the presence of diffuse adenomyosis in pregnant women with endometriosis is strongly associated 
with delivery of a FGR infant. Women with endometriosis and diffuse adenomyosis might be 
considered being at high risk of placental dysfunction and might need closer monitoring during 
pregnancy. These results are also potentially useful for preconception and prenatal counseling of 
women with both adenomyosis and endometriosis.  
Since this first study showed a strong correlation between adenomyosis and FGR in women with 
endometriosis, the second study that we performed was to ascertain the role of each endometriotic 
phenotypes, in particular ovarian endometrioma (OE) and deep endometriosis (DE), as specific risk 
factor for developing adverse perinatal outcomes in women with endometriosis.  
This retrospective study, published in 2019, aimed to investigate if perinatal and maternal 
outcomes, particularly with regard to prevalence of FGR infants, are different in pregnant women 
with OE versus those with DE without OE. This study showed, for the first time in the literature, that 
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that neither the presence of OE nor that of DE alone were considered relevant risk factors for 
placental impairment and consequently delivering FGR infants. Thus, patients affected by 
endometriosis should be treated during pregnancy as the general population, not needing closer 
monitoring.  
It is well known that FGR infants have high chances of having subtle cognitive and 
neurodevelopmental abnormalities when compared with their AGA counterparts of same 
gestational age. The main focus of this three years PhD was to prospectively evaluate the 
neurodevelopmental outcomes, particularly the neuro-motor assessment, in a cohort of FGR 
newborn at 6 and 12 months corrected age using the Bayley Scales of Infant and Toddler 
Development (3rd edition) (Bayley-III edition) and to compare them to a cohort of SGA infants and 
AGA infants. Children and their families were invited to take part in a follow-up assessment with 
Bayley Scales of Infant and Toddler Development (3rd edition)(Bayley-III) at 6 months and at 12 
months corrected age. The Bayley-III generates scores for 3 composite indices (Cognitive, Language, 
Motor) and 5 subtests (Cognitive, Expressive Communication, Receptive Communication, Fine 
Motor, Gross Motor). motion and balance) subtests. The findings of our study confirm previous 
observations that FGR infants are at increased risk for adverse neurodevelopmental outcome 
compared to AGA and SGA infants. FGR newborn had a significantly lower mean score on each 
domains (Cognitive, Language and Motor) at 6 months compared to SGA and AGA infants. However, 
at 12 months examination, while all the indices remained significantly lower in FGR group compared 
to AGA group, in the comparison with the SGA group only the motor score remained significantly 
lower in the FGR group, probably due to the fetal cerebral distribution that may affect mainly the 
motor centers.  
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Further follow-up studies, with longer follow-up, would be helpful to expand existing knowledge of 
the effects of FGR on neurodevelopment in early childhood, but it is essential to standardize 
definitions, study designs, and outcome measures.  
 
 
 
 
 
 
 
